{"content":"<li class=\"n-box-item date-title\" data-end=\"1551502799\" data-start=\"1551416400\" data-txt=\"Monday, December 23, 2019\">Friday, March  1, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3439327\" data-ts=\"1551485651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439327-synergy-pharma-gets-court-ok-to-sell-assets-to-bausch-sharesplus-4_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma gets court OK to sell assets to Bausch; shares +4.7%</a></h4><ul>   <li>Synergy Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a>) has <a href=\"https://seekingalpha.com/pr/17430815-synergy-pharmaceuticals-receives-court-approval-sale-assets-bausch-health\" target=\"_blank\">gotten court approval</a> for the sale of certain of its assets to Bausch Health Cos. (NYSE:<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>).</li>    <li>That includes all rights to Trulance (plecanatide), dolcanatide and related intellectual property.</li>    <li>The sale's now expected to close on or about March 5.</li>    <li>Bausch <a href=\"https://seekingalpha.com/news/3437545-bausch-health-acquire-synergy-assets-195m\" target=\"_blank\">agreed to acquire the assets</a> for about $195M in cash along with assuming certain liabilities.</li>    <li>Synergy is <font color=\"green\">up 4.7%</font> after hours.</li><li><strong>Update</strong>: Shares are down <font color=\"red\">19%</font> premarket (March 4).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439327\" data-linked=\"Synergy Pharma gets court OK to sell assets to Bausch; shares +4.7%\" data-tweet=\"$SGYP $BHC $SGYP-OLD - Synergy Pharma gets court OK to sell assets to Bausch; shares +4.7% https://seekingalpha.com/news/3439327-synergy-pharma-gets-court-ok-to-sell-assets-to-bausch-sharesplus-4_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3439327-synergy-pharma-gets-court-ok-to-sell-assets-to-bausch-sharesplus-4_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439322\" data-ts=\"1551479603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439322-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color=\"green\">+20.0%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color=\"green\">+15.0%</font>. <a href='https://seekingalpha.com/symbol/FLNT' title='Fluent, Inc.'>FLNT</a> <font color=\"green\">+4.6%</font>. <a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics'>AXSM</a> <font color=\"green\">+2.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/SE' title='Sea Ltd'>SE</a> <font color=\"red\">-10.5%</font>. <a href='https://seekingalpha.com/symbol/CTST' title='Canntrust Holdings Inc.'>CTST</a> <font color=\"red\">-4.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439322\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$TNXP $CIFS $FLNT - After Hours Gainers / Losers https://seekingalpha.com/news/3439322-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439322-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439320\" data-ts=\"1551478980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439320-wreplus-5_8-csiiplus-7-on-moves-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WRE +5.8%, CSII +7% on moves into SmallCap 600</a></h4><ul>   <li>Washington Real Estate Investment (NYSE:<a href='https://seekingalpha.com/symbol/WRE' title='Washington Real Estate Investment'>WRE</a>) has <font color=\"green\">risen 5.8%</font> after hours on word that it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/883758_washcardsystems6.pdf?force_download=true\" target=\"_blank\">moving into the S&amp;P SmallCap 600</a>.</li>    <li>It will replace Investment Technology Group (NYSE:<a href='https://seekingalpha.com/symbol/ITG' title='Investment Technology Group Inc.'>ITG</a>), which was acquired by Virtu Financial today. That index move is efffective prior to the open of trading next Thursday, March 7.</li>    <li>Also, Cardiovascular Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSII' title='Cardiovascular Systems, Inc.'>CSII</a>) is <font color=\"green\">up 7%</font> as it's moving into the SmallCap 600, to replace NutriSystem (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a>), which is set to be acquired by Tivity Health. That move is effective prior to the open of trading on Monday, March 11.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439320\" data-linked=\"WRE +5.8%, CSII +7% on moves into SmallCap 600\" data-tweet=\"$WRE $ITG $CSII - WRE +5.8%, CSII +7% on moves into SmallCap 600 https://seekingalpha.com/news/3439320-wreplus-5_8-csiiplus-7-on-moves-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3439320-wreplus-5_8-csiiplus-7-on-moves-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439309\" data-ts=\"1551477917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNCE\" target=\"_blank\">CNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439309-concert-pharma-secures-50m-stock-sales-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concert Pharma secures $50M stock sales agreement</a></h4><ul><li>Concert Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>) inks an <a href=\"https://www.sec.gov/Archives/edgar/data/1367920/000136792019000020/prospectussupplement-atm.htm\" target=\"_blank\">agreement </a>with Jefferies LLC for the at-the-market sale of up to $50M of its common stock. Jefferies will earn a 3% commission for its efforts.</li><li>Shares are up <font color=\"green\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439309\" data-linked=\"Concert Pharma secures $50M stock sales agreement\" data-tweet=\"$CNCE - Concert Pharma secures $50M stock sales agreement https://seekingalpha.com/news/3439309-concert-pharma-secures-50m-stock-sales-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3439309-concert-pharma-secures-50m-stock-sales-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439304\" data-ts=\"1551477619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439304-nektar-up-2-after-hours-on-encouraging-data-on-nktrminus-262-nktrminus-214-combo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar up 2% after hours on encouraging data on NKTR-262/NKTR-214 combo</a></h4><ul><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) is up <font color=\"green\">2%</font> after hours following the release of <a href=\"https://seekingalpha.com/pr/17430703-nektar-therapeutics-presents-preliminary-immune-activation-safety-clinical-activity-data\" target=\"_blank\">preliminary results</a> from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03435640?titles=reveal&amp;lead=nektar&amp;phase=1&amp;rank=1\" target=\"_blank\">REVEAL</a>, evaluating the combination of NKTR-262 and NKTR-214 in patients with locally advanced or metastatic solid tumors. The data were presented at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.</li><li>The maximum tolerated dose has not been reached, dose escalation phase is ongoing.</li><li>Treatment-related adverse events were mild or moderate. The most frequent were flu-like symptoms (69.2%), rash (46.2%), fatigue (46.2%), itchy skin (46.2%) and nausea (30.8%).</li><li>Preliminary efficacy results showed a 100% partial response rate with a 50% reduction in target lesions in two patients with relapsed/refractory melanoma who progressed on more than one prior checkpoint or I-O therapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439304\" data-linked=\"Nektar up 2% after hours on encouraging data on NKTR-262/NKTR-214 combo\" data-tweet=\"$NKTR - Nektar up 2% after hours on encouraging data on NKTR-262/NKTR-214 combo https://seekingalpha.com/news/3439304-nektar-up-2-after-hours-on-encouraging-data-on-nktrminus-262-nktrminus-214-combo?source=tweet\" data-url=\"https://seekingalpha.com/news/3439304-nektar-up-2-after-hours-on-encouraging-data-on-nktrminus-262-nktrminus-214-combo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439298\" data-ts=\"1551477017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CENX\" target=\"_blank\">CENX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439298-century-aluminum-files-300m-mixed-shelf-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Century Aluminum files $300M mixed shelf; shares +4%</a></h4><ul>    <li>Century Aluminum (NASDAQ:<a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a>) has filed a <a href=\"https://seekingalpha.com/filing/4383472\" target=\"_blank\">$300M mixed securities shelf</a> registration.</li>    <li>That covers up to that amount for sale in securities including common stock, preferred stock, debt, guarantees, warrants, depositary shares, and other items.</li>    <li>Shares <font color=\"green\">rose 3.5%</font> during the regular session and are <font color=\"green\">up another 4%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439298\" data-linked=\"Century Aluminum files $300M mixed shelf; shares +4%\" data-tweet=\"$CENX - Century Aluminum files $300M mixed shelf; shares +4% https://seekingalpha.com/news/3439298-century-aluminum-files-300m-mixed-shelf-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3439298-century-aluminum-files-300m-mixed-shelf-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439291\" data-ts=\"1551476695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTEC\" target=\"_blank\">NTEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439291-intec-pharma-files-for-200m-mixed-shelf-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intec Pharma files for $200M mixed shelf offering; shares down 3% after hours</a></h4><ul><li>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1638381/000121390019003422/fs32019_intecpharma.htm\" target=\"_blank\">preliminary prospectu</a>s for a $200M mixed shelf offering.</li><li>Shares are down 3% after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439291\" data-linked=\"Intec Pharma files for $200M mixed shelf offering; shares down 3% after hours\" data-tweet=\"$NTEC - Intec Pharma files for $200M mixed shelf offering; shares down 3% after hours https://seekingalpha.com/news/3439291-intec-pharma-files-for-200m-mixed-shelf-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3439291-intec-pharma-files-for-200m-mixed-shelf-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439286\" data-ts=\"1551476288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MO\" target=\"_blank\">MO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439286-altria-down-1-after-hours-on-fda-plan-to-restrict-sale-of-flavored-e-cigs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altria down 1% after hours on FDA plan to restrict sale of flavored e-cigs</a></h4><ul><li>Altria Group (NYSE:<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a>) eases <font color=\"red\">1%</font> after hours in apparent response to <a href=\"https://www.axios.com/fda-commissioner-e-cigarette-policy-white-house-e83f2798-2ff5-4085-b939-718b12bda0ac.html\" target=\"_blank\">reports </a>that FDA Commissioner Scott Gottlieb, M.D. has presented a plan to the White House effectively banning the sale flavored e-cigarettes in U.S. convenience stores.</li><li>Sales would not be prohibited, but convenience stores who want to sell e-cigs will have to ask people for identification before they go inside. In the case of gas stations, they would have to build a separate room to house the products and then ask for an ID before someone could enter.</li><li>Related tickers: British American Tobacco (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c. &#40;American Depository Receipts&#41;'>BTI</a>); Vape Holdings (<a href='https://seekingalpha.com/symbol/VAPE' title='Vape Holdings, Inc.'>OTCPK:VAPE</a>); Hop-On (<a href='https://seekingalpha.com/symbol/HPNN' title='Hop-on, Inc.'>OTCPK:HPNN</a>); mCIG (<a href='https://seekingalpha.com/symbol/MCIG' title='mCig, Inc.'>OTCPK:MCIG</a>); Neutra (<a href='https://seekingalpha.com/symbol/NTRR' title='Neutra Corp.'>OTCQB:NTRR</a>); VaporBrands International (<a href='https://seekingalpha.com/symbol/VAPR' title='VaporBrands International, Inc.'>OTCPK:VAPR</a>); American Heritage International (<a href='https://seekingalpha.com/symbol/AHII' title='American Heritage International Inc.'>OTC:AHII</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439286\" data-linked=\"Altria down 1% after hours on FDA plan to restrict sale of flavored e-cigs\" data-tweet=\"$MO $BTI $VAPE - Altria down 1% after hours on FDA plan to restrict sale of flavored e-cigs https://seekingalpha.com/news/3439286-altria-down-1-after-hours-on-fda-plan-to-restrict-sale-of-flavored-e-cigs?source=tweet\" data-url=\"https://seekingalpha.com/news/3439286-altria-down-1-after-hours-on-fda-plan-to-restrict-sale-of-flavored-e-cigs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>217&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439275\" data-ts=\"1551475827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439275-tonix-to-buy-back-2m-of-stock-shares-up-19-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix to buy back $2M of stock; shares up 19% after hours</a></h4><ul><li>Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) is up <font color=\"green\">19%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17430606-tonix-pharmaceuticals-announces-share-repurchase-program\" target=\"_blank\">planned repurchase</a> of up to $2M of its common stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439275\" data-linked=\"Tonix to buy back $2M of stock; shares up 19% after hours\" data-tweet=\"$TNXP - Tonix to buy back $2M of stock; shares up 19% after hours https://seekingalpha.com/news/3439275-tonix-to-buy-back-2m-of-stock-shares-up-19-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3439275-tonix-to-buy-back-2m-of-stock-shares-up-19-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439244\" data-ts=\"1551473534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439244-endo-up-3-on-favorable-fda-decision-on-vasopressin-compounding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo up 3% on favorable FDA decision on vasopressin compounding</a></h4><ul><li>Endo International plc (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"green\">+2.5%</font>) is up on more than double normal volume on the heels of an <a href=\"https://seekingalpha.com/pr/17430576-endo-announces-fda-decision-include-vasopressin-503b-bulks-list\" target=\"_blank\">FDA decision</a> against bulk compounding using vasopressin unless the compounder makes the product with an FDA-approved vasopressin product instead of bulk vasopressin.</li><li>Endo unit Par Sterile Products, LLC makes the only FDA-approved vasopressin on the market, branded as Vasostrict.</li><li>The company <a href=\"https://seekingalpha.com/news/3385916-endo-5-percent-fda-plan-restrict-compounding-vasopressin\" target=\"_blank\">sued the FDA</a> in 2017 over its interim policy allowing bulk compounding of the antidiuretic hormone using bulk product.</li><li>Chief Legal Officer Matthew Maletta says, \"...we anticipate discussing with the FDA the impact of this decision on our pending litigation in the near future.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3439244\" data-linked=\"Endo up 3% on favorable FDA decision on vasopressin compounding\" data-tweet=\"$ENDP - Endo up 3% on favorable FDA decision on vasopressin compounding https://seekingalpha.com/news/3439244-endo-up-3-on-favorable-fda-decision-on-vasopressin-compounding?source=tweet\" data-url=\"https://seekingalpha.com/news/3439244-endo-up-3-on-favorable-fda-decision-on-vasopressin-compounding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439243\" data-ts=\"1551473200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGO\" target=\"_blank\">AGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439243-assured-guaranty-sees-strong-legal-claim-on-puerto-rico-go-bonds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Assured Guaranty sees strong legal claim on Puerto Rico GO bonds</a></h4><ul><li>Assured Guaranty (<a href='https://seekingalpha.com/symbol/AGO' title='Assured Guaranty Ltd.'>AGO</a> <font color='green'>+4.7%</font>) management <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=bggfik-b\" target=\"_blank\">sees a stronger legal claim</a> on Puerto Rico's general obligation bonds, in light of the plan of adjustment for Puerto Rico's Cofina sales tax bonds resulting in holders recovering 93 cents on the dollar, BTIG analyst Mark Palmer writes in a note after AGO's earnings call.</li><li>Assured's net insured exposure to the GO bonds is $1.34B at year-end 2018.</li><li>Cofina also is a good sign for creditors at the Puerto Rico Electric Power Authority, where AGO had $848M of net insured exposure as 2018-end, according to management.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438905-assured-guaranty-q4-pvp-increases-33-percent-y-y\" target=\"_blank\">Assured Guaranty Q4 PVP increases 33% Y/Y</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439243\" data-linked=\"Assured Guaranty sees strong legal claim on Puerto Rico GO bonds\" data-tweet=\"$AGO - Assured Guaranty sees strong legal claim on Puerto Rico GO bonds https://seekingalpha.com/news/3439243-assured-guaranty-sees-strong-legal-claim-on-puerto-rico-go-bonds?source=tweet\" data-url=\"https://seekingalpha.com/news/3439243-assured-guaranty-sees-strong-legal-claim-on-puerto-rico-go-bonds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439241\" data-ts=\"1551472616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIT\" target=\"_blank\">XBIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439241-xbiotech-up-13-on-positive-bermekimab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XBiotech up 13% on positive bermekimab data</a></h4><ul><li>Thinly traded micro cap XBiotech (<a href='https://seekingalpha.com/symbol/XBIT' title='Xbiotech'>XBIT</a> <font color=\"green\">+13.4%</font>) is up on over triple normal volume, albeit on turnover of only 484K shares, on the heels of <a href=\"https://seekingalpha.com/pr/17430375-breakthrough-results-phase-2-clinical-trial-bermekimab-treatment-atopic-dermatitis-ad\" target=\"_blank\">positive results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03496974?lead=xbiotech&amp;phase=1&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> evaluating bermekimab in patients with moderate-to-severe atopic dermatitis &#40;AD&#41;. The data will be presented tomorrow at the American Academy of Dermatology Annual Meeting in Washington, DC.</li><li>After seven weeks of receiving 400 mg of bermekimab once per week, 71% of treated patients achieved EASI 75 (75% reduction in AD symptoms). Patients in this cohort also experienced a 71% reduction in itching and 84% reduction in pain.</li><li>By comparison, the proportions of AD patients in two Phase 3 studies who received Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color=\"green\">+2.1%</font>) and Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color=\"green\">+1.5%</font>) Dupixent (dupilumab) (300 mg every other week for 16 weeks) achieving EASI 75 were 51% and 44%, respectively.</li><li><a href=\"http://www.xbiotech.com/clinical/dermatology.php\" target=\"_blank\">Bermekimab </a>(MABp1) is a monoclonal antibody that binds to (inhibits) the pro-inflammatory protein interleukin-1alpha (IL-1α).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439241\" data-linked=\"XBiotech up 13% on positive bermekimab data\" data-tweet=\"$XBIT $XBIT $REGN - XBiotech up 13% on positive bermekimab data https://seekingalpha.com/news/3439241-xbiotech-up-13-on-positive-bermekimab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439241-xbiotech-up-13-on-positive-bermekimab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439235\" data-ts=\"1551470549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439235-ddd-ntnx-and-zixi-among-notable-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DDD, NTNX and ZIXI among notable tech movers</a></h4><ul><li><strong>Gainers: </strong>GlobalSCAPE (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSB' title='GlobalSCAPE, Inc'>GSB</a>) <font color=\"green\">+31%</font>. Castlight Health (NYSE:<a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a>) <font color=\"green\">+23%</font>. Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) <font color=\"green\">+22%</font>. China Finance Online (NASDAQ:<a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a>) <font color=\"green\">+12%</font>. Veritone (NASDAQ:<a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) <font color=\"red\">-32%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) <font color=\"red\">-21%</font>. DASAN Zhone Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/DZSI' title='DASAN Zhone Solutions, Inc.'>DZSI</a>) <font color=\"red\">-18%</font>. Zix Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIXI' title='Zix Corporation'>ZIXI</a>) <font color=\"red\">-15%</font>. 3D Systems Corporation (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439235\" data-linked=\"DDD, NTNX and ZIXI among notable tech movers\" data-tweet=\"$GSB $CSLT $ZS - DDD, NTNX and ZIXI among notable tech movers https://seekingalpha.com/news/3439235-ddd-ntnx-and-zixi-among-notable-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439235-ddd-ntnx-and-zixi-among-notable-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439225\" data-ts=\"1551467793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439225-huawei-to-be-arraigned-march-14-cfo-to-be-extradited-to-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huawei to be arraigned March 14; CFO to be extradited to U.S.</a></h4><ul>   <li>Huawei is set to be <a href=\"https://www.reuters.com/article/us-usa-china-huawei-tech-idUSKCN1QI550\" target=\"_blank\">arraigned on March 14</a> in U.S. District Court, and its Chief Financial Officer will be <a href=\"https://www.cnbc.com/2019/03/01/canadian-government-allows-extradition-of-huawei-cfo-to-the-us.html\" target=\"_blank\">extradited to the United States</a>.</li>    <li>The Chinese equipment maker and two affiliates will face 13 counts including bank and wire fraud and violating sanctions against Iran.</li>    <li>Separately, Huawei Device and Huawei Device USA pleaded not guilty on Thursday to charges that it conspired to steal trade secrets from T-Mobile. That trial is set for March 2020.</li>    <li>Meanwhile Canada has decided to allow the extradition of Meng Wanzhou; she'll appear in Canadian court for an extradition hearing on March 6.</li>    <li>Key rivals to Huawei (the world's biggest telecom equipment maker) are higher today: Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) <font color=\"green\">up 0.7%</font>, Ericsson (NASDAQ:<a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a>) <font color=\"green\">up 1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439225\" data-linked=\"Huawei to be arraigned March 14; CFO to be extradited to U.S.\" data-tweet=\"$NOK $ERIC - Huawei to be arraigned March 14; CFO to be extradited to U.S. https://seekingalpha.com/news/3439225-huawei-to-be-arraigned-march-14-cfo-to-be-extradited-to-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3439225-huawei-to-be-arraigned-march-14-cfo-to-be-extradited-to-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439219\" data-ts=\"1551466817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439219-independence-contract-drilling-and-halcon-resources-among-energy-materials-gainers-arcadia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Independence Contract Drilling and Halcon Resources among Energy/Materials gainers; Arcadia Biosciences and Chaparral Energy among losers</a></h4><ul><li><b>Gainers: </b>Independence Contract Drilling (NYSE:<a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling'>ICD</a>) <font color=\"green\">+14%</font>. Halcon Resources (NYSE:<a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a>) <font color=\"green\">+9%</font>. Yield10 Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a>) <font color=\"green\">+8%</font>. Chesapeake Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a>) <font color=\"green\">+7%</font>. Flotek Industries (NYSE:<a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a>) <font color=\"red\">-12%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy Inc'>CHAP</a>) <font color=\"red\">-9%</font>. Blueknight Energy Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/BKEP' title='Blueknight Energy Partners'>BKEP</a>) <font color=\"red\">-8%</font>. Roan Resources (NYSE:<a href='https://seekingalpha.com/symbol/ROAN' title='Roan Resources, Inc.A'>ROAN</a>) <font color=\"red\">-6%</font>. Altus Midstream (NASDAQ:<a href='https://seekingalpha.com/symbol/ALTM' title='Altus Midstream Company'>ALTM</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439219\" data-linked=\"Independence Contract Drilling and Halcon Resources among Energy/Materials gainers; Arcadia Biosciences and Chaparral Energy among losers\" data-tweet=\"$ICD $HKRS $YTEN - Independence Contract Drilling and Halcon Resources among Energy/Materials gainers; Arcadia Biosciences and Chaparral Energy among losers https://seekingalpha.com/news/3439219-independence-contract-drilling-and-halcon-resources-among-energy-materials-gainers-arcadia?source=tweet\" data-url=\"https://seekingalpha.com/news/3439219-independence-contract-drilling-and-halcon-resources-among-energy-materials-gainers-arcadia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439218\" data-ts=\"1551466408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439218-hulu-live-tv-hitting-2m-customer-mark-moving-second-place\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hulu live TV hitting 2M-customer mark, moving into second place</a></h4><ul>   <li>Hulu's live TV service is ready to move into second place among the live-TV streamers, by <a href=\"https://www.bloomberg.com/news/articles/2019-03-01/hulu-youtube-are-said-to-snare-3-million-customers-for-live-tv\" target=\"_blank\">nearing 2M subscribers</a>.</li>    <li>That would move it past DirecTV Now (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"red\">-1.3%</font>), which lost 267,000 customers in Q4 to settle near 1.6M, but still have Hulu's live service trailing Sling TV (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"red\">-0.3%</font>), which had 2.42M subs at the end of 2018. Rival YouTube TV (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color=\"green\">+1.7%</font>) has passed 1M subs, Bloomberg says.</li>    <li>Hulu -- for the moment -- is owned by Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color=\"green\">+1%</font>), Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color=\"green\">+1.1%</font>) and Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>), each with a 30% stake, and WarnerMedia (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) with 10%.</li>    <li>But Disney is getting ready to take over Fox's share through their $71B asset deal, and it reportedly has been in <a href=\"https://seekingalpha.com/news/3438024-variety-disney-talks-acquire-and-ts-hulu-stake\" target=\"_blank\">active talks to buy WarnerMedia's 10%</a>.</li>    <li>Hulu recently raised its live streaming price to $45/month from $40; Sling is <a href=\"https://seekingalpha.com/news/3437917-sling-tv-launches-price-promotion-boost-subscriptions\" target=\"_blank\">promoting discounts to maintain its lead</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439218\" data-linked=\"Hulu live TV hitting 2M-customer mark, moving into second place\" data-tweet=\"$GOOG $GOOGL $FOX - Hulu live TV hitting 2M-customer mark, moving into second place https://seekingalpha.com/news/3439218-hulu-live-tv-hitting-2m-customer-mark-moving-second-place?source=tweet\" data-url=\"https://seekingalpha.com/news/3439218-hulu-live-tv-hitting-2m-customer-mark-moving-second-place\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439215\" data-ts=\"1551465501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMK\" target=\"_blank\">WMK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439215-weis-markets-dips-after-amazon-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weis Markets dips after Amazon report</a></h4><ul> <li>Weis Markets (NYSE:<a href='https://seekingalpha.com/symbol/WMK' title='Weis Markets Inc'>WMK</a>) is <font color=\"red\">down 1.44%</font> after being in positive territory for most of the morning.</li> <li>The share price reversal could be tied to a report that indicates Amazon is planning a new grocery store chain.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439204-amazon-plans-new-grocery-chain-report\" target=\"_blank\">Amazon plans new grocery chain - report</a> (March 1)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439215\" data-linked=\"Weis Markets dips after Amazon report\" data-tweet=\"$WMK - Weis Markets dips after Amazon report https://seekingalpha.com/news/3439215-weis-markets-dips-after-amazon-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3439215-weis-markets-dips-after-amazon-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439214\" data-ts=\"1551465060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439214-broadcasters-surge-alongside-strong-results-from-scripps-tegna\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcasters surge alongside strong results from Scripps, Tegna</a></h4><ul>   <li>Broadcast companies are broadly higher today after solid earnings from a couple of their peers.</li>    <li>Scripps (NASDAQ:<a href='https://seekingalpha.com/symbol/SSP' title='The E.W. Scripps Company'>SSP</a>) is <font color=\"green\">up 4.2%</font> now after <a href=\"https://seekingalpha.com/news/3439133-scripps-plus-2_6-percent-sharp-revenue-gain-q4\" target=\"_blank\">boosting its revenues</a> locally and nationally, and Tegna (NYSE:<a href='https://seekingalpha.com/symbol/TGNA' title='TEGNA'>TGNA</a>) is <font color=\"green\">up 14.7%</font> to its highest point in more than a year following its own <a href=\"https://seekingalpha.com/news/3439155-tegna-plus-13_4-percent-hitting-record-revenues-ebitda\" target=\"_blank\">record revenues</a>.</li>    <li>Also higher today are peers Nexstar Media Group (NASDAQ:<a href='https://seekingalpha.com/symbol/NXST' title='Nexstar Media Group, Inc.'>NXST</a>), <font color=\"green\">up 4.1%</font>; Sinclair Broadcast Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a>), <font color=\"green\">up 2%</font>; Gray Television (NYSE:<a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a>), <font color=\"green\">up 4.5%</font>; Meredith (NYSE:<a href='https://seekingalpha.com/symbol/MDP' title='Meredith Corporation'>MDP</a>), <font color=\"green\">up 1.8%</font>; and Liberty Media (NASDAQ:<a href='https://seekingalpha.com/symbol/FWONA' title='Liberty Media Corp'>FWONA</a>), <font color=\"green\">up 5.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439214\" data-linked=\"Broadcasters surge alongside strong results from Scripps, Tegna\" data-tweet=\"$SSP $TGNA $NXST - Broadcasters surge alongside strong results from Scripps, Tegna https://seekingalpha.com/news/3439214-broadcasters-surge-alongside-strong-results-from-scripps-tegna?source=tweet\" data-url=\"https://seekingalpha.com/news/3439214-broadcasters-surge-alongside-strong-results-from-scripps-tegna\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439206\" data-ts=\"1551463068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439206-china-internet-nationwide-financial-services-leads-financial-gainers-washington-prime-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Internet Nationwide Financial Services leads financial gainers; Washington Prime Group and Ashford Hospitality Trust among losers</a></h4><ul><li><b>Gainers:</b> China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+22%</font>. PPDAI Group (NYSE:<a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a>) <font color=\"green\">+10%</font>. eHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) <font color=\"green\">+10%</font>. MBIA (NYSE:<a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a>) <font color=\"green\">+6%</font>. Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLRP' title='Wheeler Real Estate Investment Trust Inc. Cum Conv Pfd Shs Series B'>WHLRP</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Universal Insurance Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a>) <font color=\"red\">-18%</font>. Washington Prime Group (NYSE:<a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a>) <font color=\"red\">-11%</font>. Ashford Hospitality Trust (NYSE:<a href='https://seekingalpha.com/symbol/AHT' title='Ashford Hospitality Trust, Inc.'>AHT</a>) <font color=\"red\">-10%</font>. Senior Housing Properties Trust (NYSE:<a href='https://seekingalpha.com/symbol/SNH' title='Senior Housing Properties Trust'>SNH</a>) <font color=\"red\">-8%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439206\" data-linked=\"China Internet Nationwide Financial Services leads financial gainers; Washington Prime Group and Ashford Hospitality Trust among losers\" data-tweet=\"$CIFS $FINV $EHTH - China Internet Nationwide Financial Services leads financial gainers; Washington Prime Group and Ashford Hospitality Trust among losers https://seekingalpha.com/news/3439206-china-internet-nationwide-financial-services-leads-financial-gainers-washington-prime-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3439206-china-internet-nationwide-financial-services-leads-financial-gainers-washington-prime-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439205\" data-ts=\"1551463024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439205-healthcare-and-tech-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare and Tech dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+130%</font>. Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) <font color=\"green\">+42%</font>. Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) <font color=\"green\">+30%</font>. GlobalSCAPE (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSB' title='GlobalSCAPE, Inc'>GSB</a>) <font color=\"green\">+29%</font>. Castlight Health (NYSE:<a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a>) <font color=\"green\">+24%</font>. Farfetch Limited (NYSE:<a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch'>FTCH</a>) <font color=\"green\">+23%</font>. Sequential Brands Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"green\">+20%</font>. Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) <font color=\"green\">+21%</font>. Bio-Rad Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/BIO' title='Bio-Rad Laboratories, Inc.'>BIO</a>) <font color=\"green\">+19%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+19%</font>.</li> <li><strong>Losers: </strong>ImmunoGen(NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"red\">-47%</font>. Intrexon Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <font color=\"red\">-37%</font>. Nutanix(NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) <font color=\"red\">-31%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) <font color=\"red\">-22%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIIK' title='PHI, Inc. - Non'>PHIIK</a>) <font color=\"red\">-22%</font>. Mersana Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRSN' title='Mersana Therapeutics'>MRSN</a>) <font color=\"red\">-21%</font>. Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) <font color=\"red\">-20%</font>. Universal Insurance Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a>) <font color=\"red\">-19%</font>. IMV (NASDAQ:<a href='https://seekingalpha.com/symbol/IMV' title='IMV Inc.'>IMV</a>) <font color=\"red\">-18%</font>. DASAN Zhone Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/DZSI' title='DASAN Zhone Solutions, Inc.'>DZSI</a>) <font color=\"red\">-17%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439205\" data-linked=\"Healthcare and Tech dominate midday movers\" data-tweet=\"$BPTH $PBYI $LXRX - Healthcare and Tech dominate midday movers https://seekingalpha.com/news/3439205-healthcare-and-tech-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439205-healthcare-and-tech-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439204\" data-ts=\"1551462652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439204-amazon-plans-new-grocery-chain-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon plans new grocery chain - report</a></h4><ul><li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) plans to open dozens of grocery stores across the U.S. that have a lower price point and broader offerings than its Whole Foods stores, according to <a href=\"https://www.wsj.com/articles/amazon-to-launch-new-grocery-store-business-sources-say-11551461887\" target=\"_blank\">WSJ sources</a>.</li><li>The first store could open in Los Angeles as early as the end of this year.</li><li>The tech giant is also pursuing an acquisition strategy to widen the new supermarket brand with eyes on regional grocery chains that have about a dozen operating stores.</li><li>On the move with the news: Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-4%</font>), Walgreens Boots (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='red'>-6.4%</font>), Walmart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color='red'>-0.9%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439204\" data-linked=\"Amazon plans new grocery chain - report\" data-tweet=\"$AMZN $KR $WBA - Amazon plans new grocery chain - report https://seekingalpha.com/news/3439204-amazon-plans-new-grocery-chain-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3439204-amazon-plans-new-grocery-chain-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>194&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439200\" data-ts=\"1551461768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TENX\" target=\"_blank\">TENX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439200-tenax-therapeutics-up-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenax Therapeutics up 26%</a></h4><ul><li>Nano cap Tenax Therapeutics (<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a> <font color=\"green\">+26.4%</font>) is up on a 5x surge in volume on no apparent news.</li><li>In December 2018, it inked an <a href=\"https://www.sec.gov/Archives/edgar/data/34956/000165495418013810/tenx_8k.htm\" target=\"_blank\">agreement </a>with Ladenburg Thalmann to underwrite an offering of ~5.2M Units, each consisting of one share of Series A convertible preferred stock, one two-year warrant to purchase one common share at $1.93 and one five-year warrant to purchase one common share at $1.93, at a price of $1.93 per Unit.</li><li>Net proceeds should be ~$9M.</li><li>Shares are currently exchanging hands at $1.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439200\" data-linked=\"Tenax Therapeutics up 26%\" data-tweet=\"$TENX - Tenax Therapeutics up 26% https://seekingalpha.com/news/3439200-tenax-therapeutics-up-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3439200-tenax-therapeutics-up-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439198\" data-ts=\"1551461398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439198-analysts-up-splunk-targets-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts up Splunk targets after earnings</a></h4><ul><li>Jefferies maintains a Buy rating on Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) after <a href=\"https://seekingalpha.com/news/3438857-splunk-plus-3_7-percent-q4-beats-upside-fy-outlook\" target=\"_blank\">earnings</a> and raises the PT from $137 to $157 saying that while the new accounting standards might cause some confusion, Splunk is \"likely even stronger than it appears.\"</li><li>Bernstein's Mark Moerdler increases his target from $119 to $131 while noting, \"We obviously got off the bus too early on this one.\"</li><li>Moerdler has a Market Perform rating.</li><li>Splunk shares are <font color=\"red\">down 0.8%</font> to $134.74.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439198\" data-linked=\"Analysts up Splunk targets after earnings\" data-tweet=\"$SPLK - Analysts up Splunk targets after earnings https://seekingalpha.com/news/3439198-analysts-up-splunk-targets-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3439198-analysts-up-splunk-targets-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439195\" data-ts=\"1551460754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTWO\" target=\"_blank\">QTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439195-q2-holdings-gains-keybanc-boosts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Q2 Holdings gains as KeyBanc boosts price target</a></h4><ul><li>Q2 Holdings (<a href='https://seekingalpha.com/symbol/QTWO' title='Q2 Holdings, Inc.'>QTWO</a> <font color='green'>+3.1%</font>) jumps<font color=\"green\"> as much as 4.6%</font> after KeyBanc analyst Arvind Ramnani boosts his price target to $83 from $77, saying the virtual banking software company's product development and strategic acquisitions increase its addressable market and \"robust\" financial model.</li><li>By offering banks deposit and lending products on the same platform, \"QTWO can increase wallet share at existing clients while improving its competitive positioning at larger banks due to increased functionality and capabilities,\" Ramnani wrote.</li><li>Sees Q2's initial 2020 revenue targets as conservative--\"increasing addressable market provides incremental headroom and tailwinds to drive further share gains and revenue growth.\"</li><li><a href=\"https://seekingalpha.com/symbol/QTWO/earnings/analyst_ratings\" target=\"_blank\">Analyst ratings</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420497-stephens-bumps-q2-overweight\" target=\"_blank\">Stephens bumps Q2 up to Overweight</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439195\" data-linked=\"Q2 Holdings gains as KeyBanc boosts price target\" data-tweet=\"$QTWO - Q2 Holdings gains as KeyBanc boosts price target https://seekingalpha.com/news/3439195-q2-holdings-gains-keybanc-boosts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3439195-q2-holdings-gains-keybanc-boosts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439194\" data-ts=\"1551460645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439194-neophotonicsminus-11-analysts-trim-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoPhotonics -11% as analysts trim targets</a></h4><ul>   <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) is <font color=\"red\">11.2% lower</font> today after its <a href=\"https://seekingalpha.com/news/3438921-neophotonics-minus-4_8-percent-amid-light-q1-profit-guidance\" target=\"_blank\">Q4 earnings</a> contained a light outlook for the current quarter.</li>    <li>B. Riley cut its price target to a Street-low $7.75 from $8.25; that target now implies 2% upside after today's tumble.</li>    <li>Heavy exposure to Huawei is the issue there, analyst Dave Kang says; the company gets nearly half its revenue from the Chinese gear maker, which is facing regulatory scrutiny and loss of business over spying suspicions.</li>    <li>Cowen also lowered its target, to $11 from $12, with an eye to eventual improvement based on growing demand.</li>    <li><a href=\"https://seekingalpha.com/article/4245547-neophotonics-corporation-nptn-ceo-tim-jenks-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439194\" data-linked=\"NeoPhotonics -11% as analysts trim targets\" data-tweet=\"$NPTN - NeoPhotonics -11% as analysts trim targets https://seekingalpha.com/news/3439194-neophotonicsminus-11-analysts-trim-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3439194-neophotonicsminus-11-analysts-trim-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439192\" data-ts=\"1551460576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASTE\" target=\"_blank\">ASTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439192-astec-industriesplus-7-on-q4-earnings-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Astec Industries +7% on Q4 earnings beats</a></h4><div><ul><li>Astec Industries (<a href='https://seekingalpha.com/symbol/ASTE' title='Astec Industries, Inc.'>ASTE</a> <font color=\"green\">+7.8%</font>)  reported Q4 net sales of $317.01M an increase of 1.5% Y/Y, domestic sales increased by 1.1% Y/Y and international sales increased by 2.8% Y/Y.</li><li>Revenue by segments: Infrastructure $124.93M (-14.8% Y/Y); Aggregate and Mining $116.06M (+20.3% Y/Y); and Energy $76.01M (+9.9% Y/Y).</li><li>Company reported a gross loss of $1.63M and gross margin <font color=\"red\">declined by 2060 bps</font> to -0.5%.</li><li>SG&amp;A expenses were $54.73M (+22.3% Y/Y) and margin of 17.3% <font color=\"red\">up by 294 bps</font>.</li><li>The backlog was $345M (-16.2% Y/Y), with Infrastructure at $149.44M (-37.6% Y/Y); Aggregate and Mining at $130.69M (+11.7% Y/Y); and Energy at $64.83M (+17.9% Y/Y).</li><li>For the quarter Company recorded charges totaling $90.6M resulting from a write-off related to the Hazlehurst wood pellet plant, an inventory valuation adjustment, the exit of a subsidiary business in Germany and an impairment of goodwill.</li><li>Company has Cash and cash equivalents of $25.82M as of December 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439006-astec-beats-0_04-beats-revenue\" target=\"_blank\">Astec beats by $0.04, beats on revenue</a> (March 1)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3439192\" data-linked=\"Astec Industries +7% on Q4 earnings beats\" data-tweet=\"$ASTE - Astec Industries +7% on Q4 earnings beats https://seekingalpha.com/news/3439192-astec-industriesplus-7-on-q4-earnings-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3439192-astec-industriesplus-7-on-q4-earnings-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439185\" data-ts=\"1551459623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439185-energous-and-sequential-brands-among-consumer-gainers-tesla-and-vuzix-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous and Sequential Brands among consumer gainers; Tesla and Vuzix among losers</a></h4><ul><li><b>Gainers: </b>Sequential Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"green\">+27%</font>. Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a>) <font color=\"green\">+16%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) <font color=\"green\">+9%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+7%</font>. JAKKS Pacific (NASDAQ:<a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>CCA Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/CAW' title='CCA Industries Inc'>CAW</a>) <font color=\"red\">-9%</font>. Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) <font color=\"red\">-8%</font>. Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439185\" data-linked=\"Energous and Sequential Brands among consumer gainers; Tesla and Vuzix among losers\" data-tweet=\"$SQBG $PLAG $WATT - Energous and Sequential Brands among consumer gainers; Tesla and Vuzix among losers https://seekingalpha.com/news/3439185-energous-and-sequential-brands-among-consumer-gainers-tesla-and-vuzix-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439185-energous-and-sequential-brands-among-consumer-gainers-tesla-and-vuzix-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439181\" data-ts=\"1551458828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTLK\" target=\"_blank\">OTLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439181-outlook-advancing-eye-disease-candidate-onsminus-5010\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Outlook advancing eye disease candidate ONS-5010</a></h4><ul><li>Outlook Therapeutics (<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics Inc'>OTLK</a> <font color=\"red\">-4.5%</font>) has <a href=\"https://seekingalpha.com/pr/17429967-outlook-therapeutics-submits-ind-application-onsminus-5010-fda\" target=\"_blank\">filed an IND</a> with the FDA seeking sign-off to start a U.S. Phase 3 clinical trial evaluating ONS-5010 for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema &#40;DME&#41; and branch retinal vein occlusion &#40;BRVO&#41;. Enrollment should start next month.</li><li>The U.S. portion, part of a second Phase 3 that includes sites in Australia and New Zealand, will compare ONS-5010 to Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color=\"green\">+0.1%</font>) Lucentis (ranibizumab) in wet AMD. Enrollment in the first Phase 3 (in Australia) should be completed this month.</li><li>ONS-5010 is an ophthalmic formulation of Roche's cancer med Avastin (bevacizumab) that is administered via intravitreal injection (into the eye). The company says this off-label use of Avastin accounts for about half of all wet AMD prescriptions in the U.S.</li><li>Shares are down on below-average volume. A capital raise is looming. The company filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1649989/000114420419009191/tv514152-s1.htm\" target=\"_blank\">prospectus</a> last week for a stock offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439181\" data-linked=\"Outlook advancing eye disease candidate ONS-5010\" data-tweet=\"$OTLK $RHHBY - Outlook advancing eye disease candidate ONS-5010 https://seekingalpha.com/news/3439181-outlook-advancing-eye-disease-candidate-onsminus-5010?source=tweet\" data-url=\"https://seekingalpha.com/news/3439181-outlook-advancing-eye-disease-candidate-onsminus-5010\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439178\" data-ts=\"1551458569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRSS\" target=\"_blank\">BRSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439178-on-global-brass-and-copper-holdings-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Global Brass and Copper Holdings Q4 results</a></h4><ul><li>Global Brass and Copper Holdings (<a href='https://seekingalpha.com/symbol/BRSS' title='Global Brass and Copper Holdings'>BRSS</a> <font color=\"red\">-2%</font>) reported Q4 revenue of $404.3M a decrease of 4.8% Y/Y, attributed to a decrease in the metal cost recovery component.</li><li>Shipments volumes increased 2.7% Y/Y to 131.1M pounds, with Olin Brass at 60.4M (+2.9% Y/Y); Chase Brass at 47.5M (-7.8% Y/Y); and A.J. Oster at 31.7M (+22.9% Y/Y).</li><li>Net sales by segments: Olin Brass $183.1M (-5.7% Y/Y); Chase Brass $132M (-12.6% Y/Y); and A.J. Oster $110.6M (+14% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">declined by 165 bps</font> to 9.1%; and operating margin <font color=\"red\">declined by 241 bps</font> to 3.1%.</li><li>Adj. EBITDA was 25.3M (-13.9% Y/Y) and margin <font color=\"red\">declined by 66 bps </font>to 6.3%.</li><li>SG&amp;A expenses increased by 9% Y/Y to $24.2M and margin was 6% <font color=\"red\">up by 76 bps</font>.</li><li>Company generated $40.1M of cash from the combination of operating and investing activities largely due to changes in working capital and cash earnings, partially offset by capital expenditures.</li><li><strong>FY19 Guidance:</strong> Shipment volumes in range of 555M to 595M pounds; Adj. EBITDA $129M to $139M; and Adj. EBITDA $120M to $130M (under new methodology).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438791-global-brass-copper-eps-line-misses-revenue\" target=\"_blank\">Global Brass and Copper EPS in-line, misses on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439178\" data-linked=\"More on Global Brass and Copper Holdings Q4 results\" data-tweet=\"$BRSS - More on Global Brass and Copper Holdings Q4 results https://seekingalpha.com/news/3439178-on-global-brass-and-copper-holdings-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3439178-on-global-brass-and-copper-holdings-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439179\" data-ts=\"1551458543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYV\" target=\"_blank\">LYV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439179-live-nationplus-8_8-after-record-results-strong-look-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Live Nation +8.8% after record results, strong look ahead</a></h4><ul>   <li>Live Nation (NYSE:<a href='https://seekingalpha.com/symbol/LYV' title='Live Nation Entertainment, Inc.'>LYV</a>) is <font color=\"green\">up 8.8%</font> after its <a href=\"https://seekingalpha.com/news/3438794-live-nation-entertainment-beats-revenue\" target=\"_blank\">revenues topped expectations</a> and the company signaled higher ticket volumes, though operating income fell short of consensus.</li>    <li>As of mid-February, tickets sold for 2019 concerts were up by double digits Y/Y, as were confirmed concert events.</li>    <li>The company also said sponsorship and advertising committed net revenue is also up double digits and over 70% of 2019 projections.</li>    <li><a href=\"https://seekingalpha.com/pr/17429396-live-nation-entertainment-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li>    <li><a href=\"https://seekingalpha.com/article/4245526-live-nation-entertainment-inc-lyv-ceo-michael-rapino-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439179\" data-linked=\"Live Nation +8.8% after record results, strong look ahead\" data-tweet=\"$LYV - Live Nation +8.8% after record results, strong look ahead https://seekingalpha.com/news/3439179-live-nationplus-8_8-after-record-results-strong-look-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3439179-live-nationplus-8_8-after-record-results-strong-look-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439175\" data-ts=\"1551457603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOP\" target=\"_blank\">KOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439175-koppers-holdings-up-4-post-q4-earnings-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Koppers Holdings up 4% post Q4 earnings, mixed guidance</a></h4><ul><li>Koppers Holdings (NYSE:<a href='https://seekingalpha.com/symbol/KOP' title='Koppers Holdings Inc.'>KOP</a>) <font color=\"green\">gains 4%</font> after <a href=\"https://seekingalpha.com/pr/17429989-koppers-holdings-inc-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">mixed Q4 results</a> with 16% Y/Y revenue growth.</li><li>The company issues mixed guidance for FY19, sees EPS of $2.87-3.32 vs. a consensus $3.70; FY19 revenue of $1.8-1.9B vs. a consensus $1.8B.</li><li>On an adjusted basis, Koppers expects EBITDA of ~$210-$225M for 2019, compared with ~$222M in the prior year.</li><li>The company is anticipating higher y/y interest expenses and depreciation and amortization costs in 2019.</li><li>The company plans to reduce debt by a minimum of $80M in 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439059-koppers-holdings-beats-0_14-misses-revenue\" target=\"_blank\">Koppers Holdings beats by $0.14, misses on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439175\" data-linked=\"Koppers Holdings up 4% post Q4 earnings, mixed guidance\" data-tweet=\"$KOP - Koppers Holdings up 4% post Q4 earnings, mixed guidance https://seekingalpha.com/news/3439175-koppers-holdings-up-4-post-q4-earnings-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3439175-koppers-holdings-up-4-post-q4-earnings-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439173\" data-ts=\"1551457128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRNB\" target=\"_blank\">PRNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439173-principia-bio-up-3-on-positive-prn2246-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Principia Bio up 3% on positive PRN2246 data</a></h4><ul><li>Thinly traded Principia Biopharma (<a href='https://seekingalpha.com/symbol/PRNB' title='Principia Biopharma'>PRNB</a> <font color=\"green\">+3.4%</font>) is up on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17429937-principia-biopharma-presents-phase-1-clinical-data-cns-penetrating-btk-inhibitor-candidate\" target=\"_blank\">Phase 1 data</a> on multiple sclerosis candidate PRN2246, a Bruton's tyrosine kinase &#40;BTK&#41; inhibitor that crosses the blood-brain barrier. The results were presented at ACTRIMS in Dallas, TX.</li><li>PRN2246 was well-tolerated with only mild treatment-related adverse events. Exposure was dose-dependent with rapid absorption and a clearance profile that met expectations. Exposure in cerebrospinal fluid &#40;CSF&#41; was achieved in all subjects who underwent lumbar puncture which confirmed that PRN2246 crossed the blood-brain barrier.</li><li>Exclusive licensee Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color=\"green\">+1%</font>) will now proceed with Phase 2 development under the candidate name SAR442168.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439173\" data-linked=\"Principia Bio up 3% on positive PRN2246 data\" data-tweet=\"$PRNB $SNY - Principia Bio up 3% on positive PRN2246 data https://seekingalpha.com/news/3439173-principia-bio-up-3-on-positive-prn2246-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439173-principia-bio-up-3-on-positive-prn2246-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439171\" data-ts=\"1551456879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439171-snoop-dogg-assists-on-canopy-martha-stewart-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snoop Dogg assists on Canopy-Martha Stewart deal</a></h4><ul> <li>Snoop Dogg is being credited with <a href=\"https://www.cnbc.com/2019/03/01/martha-stewart-had-help-on-her-deal-with-weed-grower-canopy-snoop-dogg.html\" target=\"_blank\">linking</a> up Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"red\">-0.1%</font>) with Martha Stewart ahead of the roll-out of new consumer products. Snoop and Martha have met several times on the TV circuit.</li> <li>\"I'm running a very large marijuana company and here I am meeting a person considered a leader on all things etiquette,\" gushes Canopy CEO Bruce Linton about the Martha visit to the company's HQ.</li> <li>Amid the buzz over the Canopy-Snoop-Martha connection, it's shares of partner Sequential Brands Group (<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color=\"green\">+15.5%</font>) that have somewhat quietly racked up a 57% three-session gain.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438528-martha-stewart-advise-canopy-growth-sequential-brands-cbd-marketing\" target=\"_blank\">Martha Stewart to advise Canopy Growth and Sequential Brands on CBD marketing</a> (Feb. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438649-sequential-brands-plus-28-percent-martha-stewart-buzz\" target=\"_blank\">Sequential Brands +28% on Martha Stewart buzz</a> (Feb. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439171\" data-linked=\"Snoop Dogg assists on Canopy-Martha Stewart deal\" data-tweet=\"$CGC $SQBG - Snoop Dogg assists on Canopy-Martha Stewart deal https://seekingalpha.com/news/3439171-snoop-dogg-assists-on-canopy-martha-stewart-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3439171-snoop-dogg-assists-on-canopy-martha-stewart-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439165\" data-ts=\"1551456056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439165-puma-biotechnology-and-lexicon-pharmaceuticals-among-healthcare-gainers-immunogen-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Biotechnology and Lexicon Pharmaceuticals among healthcare gainers; ImmunoGen leads the losers</a></h4><ul><li><b>Gainers: </b>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"green\">+151%</font>. Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) <font color=\"green\">+40%</font>. Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"green\">+23%</font>. Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) <font color=\"green\">+19%</font>. Bio-Rad Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/BIO' title='Bio-Rad Laboratories, Inc.'>BIO</a>) <font color=\"green\">+17%</font>.</li><li><b>Losers: </b>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"red\">-49%</font>. Intrexon (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <font color=\"red\">-31%</font>. Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) <font color=\"red\">-20%</font>. IMV (NASDAQ:<a href='https://seekingalpha.com/symbol/IMV' title='IMV Inc.'>IMV</a>) <font color=\"red\">-19%</font>. Mersana Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRSN' title='Mersana Therapeutics'>MRSN</a>) <font color=\"red\">-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439165\" data-linked=\"Puma Biotechnology and Lexicon Pharmaceuticals among healthcare gainers; ImmunoGen leads the losers\" data-tweet=\"$BPTH $PBYI $TENX - Puma Biotechnology and Lexicon Pharmaceuticals among healthcare gainers; ImmunoGen leads the losers https://seekingalpha.com/news/3439165-puma-biotechnology-and-lexicon-pharmaceuticals-among-healthcare-gainers-immunogen-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3439165-puma-biotechnology-and-lexicon-pharmaceuticals-among-healthcare-gainers-immunogen-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439164\" data-ts=\"1551456026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439164-insider-buying-absent-national-beverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insider buying absent at National Beverage</a></h4><ul> <li>Barron's points out insiders at National Beverage (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-2.5%</font>) aren't <a href=\"https://www.barrons.com/articles/lacroix-national-beverage-stock-slumps-51551390290\" target=\"_blank\">buying</a> more shares even after the benefited from the huge special dividend paid out by the beverage company.</li> <li>\"In fact, apart from exercising options and gifting stock, National Beverage insiders haven\u2019t registered any activity in nearly four years,\" notes the publication.</li> <li>Shares of FIZZ are down 23% over the last 90 days.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439164\" data-linked=\"Insider buying absent at National Beverage\" data-tweet=\"$FIZZ - Insider buying absent at National Beverage https://seekingalpha.com/news/3439164-insider-buying-absent-national-beverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3439164-insider-buying-absent-national-beverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439159\" data-ts=\"1551454977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439159-bombardier-doubles-down-on-bond-buybacks-in-hot-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bombardier doubles down on bond buybacks in hot market</a></h4><ul>   <li>Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a> <font color=\"green\">+2.8%</font>, <a href='https://seekingalpha.com/symbol/BRDBF' title='Bumi Armada Bhd'>OTC:BRDBF</a> <font color=\"green\">+2.4%</font>) has announced a <a href=\"https://seekingalpha.com/pr/17429709-bombardier-announces-cash-tender-offer-us-975000-000-aggregate-purchase-price-6-senior-notes\" target=\"_blank\">cash tender offer</a> to buy up to $975M of 2021 notes.</li>    <li>With a separate tender of $850M in 7.75% bonds due 2020, it's doubling bond buybacks to as much as $1.83B.</li>    <li>That follows stronger-than-expected results from a new bond issuance yesterday, where the company doubled the offering to $2B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439159\" data-linked=\"Bombardier doubles down on bond buybacks in hot market\" data-tweet=\"$BDRAF $BRDBF - Bombardier doubles down on bond buybacks in hot market https://seekingalpha.com/news/3439159-bombardier-doubles-down-on-bond-buybacks-in-hot-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3439159-bombardier-doubles-down-on-bond-buybacks-in-hot-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439158\" data-ts=\"1551454914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439158-analyst-cautions-erase-3d-systems-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst cautions erase 3D Systems gains</a></h4><ul><li>Analysts caution on 3D's (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>) growth forecast after yesterday's mixed <a href=\"https://seekingalpha.com/news/3438765-3d-systems-gains-plus-76-percent-printer-units\" target=\"_blank\">Q4 results</a> with Needham noting the company faces tougher comparisons in the first half. The firm expects higher than normal seasonality in Q1.</li><li>William Blair cautions on margin pressure, difficult comps, and increasing competitions, which could all be headwinds in 2019.</li><li>3D shares are <font color=\"red\">down 11.3%,</font> erasing the post-earnings gains. Peer Stratasys (<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a> <font color='red'>-1.6%</font>) is along for the ride.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439158\" data-linked=\"Analyst cautions erase 3D Systems gains\" data-tweet=\"$DDD $SSYS - Analyst cautions erase 3D Systems gains https://seekingalpha.com/news/3439158-analyst-cautions-erase-3d-systems-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3439158-analyst-cautions-erase-3d-systems-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439155\" data-ts=\"1551454168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGNA\" target=\"_blank\">TGNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439155-tegnaplus-13_4-after-hitting-record-revenues-ebitda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tegna +13.4% after hitting record revenues, EBITDA</a></h4><ul>    <li>Tegna (NYSE:<a href='https://seekingalpha.com/symbol/TGNA' title='TEGNA'>TGNA</a>) has <font color=\"green\">jumped 13.4%</font> after topping estimates with record revenues both in political and subscription areas.</li>    <li>Excluding record political advertising performance in an election year, total revenues still increased 5%.</li>    <li>EBITDA hit a record as well, up 61% to $273M, as did free cash flow ($167M). Net cash flow from operations was $195M.</li>    <li>And EPS rose 131%.</li>    <li>Revenue breakout: Advertising and Marketing Services, $277.1M (down 6.5%); Subscription, $218.5M (up 22.4%); Political, $139.9M (up from $9.9M); other, $6.7M (up 19.6%).</li>    <li>For Q1 it's guiding to non-GAAP revenue growth in the mid- to high single digits (excluding Olympics and political), along with total operating expenses up in mid-single-digits (flat to up slightly, excluding programming).</li>    <li>For the full year, it expects subscription revenues to grow in the mid-teens, and free cash flow about 18-19% of 2019-2020 revenue.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439029-tegna-beats-0_06-beats-revenue\" target=\"_blank\">TEGNA beats by $0.06, beats on revenue</a> (Mar. 01 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17429922-tegna-inc-reports-record-2018-fourth-quarter-strong-full-year-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439155\" data-linked=\"Tegna +13.4% after hitting record revenues, EBITDA\" data-tweet=\"$TGNA - Tegna +13.4% after hitting record revenues, EBITDA https://seekingalpha.com/news/3439155-tegnaplus-13_4-after-hitting-record-revenues-ebitda?source=tweet\" data-url=\"https://seekingalpha.com/news/3439155-tegnaplus-13_4-after-hitting-record-revenues-ebitda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439140\" data-ts=\"1551454053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439140-intrexon-down-31-after-soft-q4-results-capital-needs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon down 31% after soft Q4 results, capital needs</a></h4><ul><li>Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color=\"red\">-30.8%</font>), at one time valued at more than $7B, continues its downward spiral after posting <a href=\"https://seekingalpha.com/news/3438774-intrexon-q4-top-line-44-percent-shares-1-percent-hours\" target=\"_blank\">tepid Q4 results</a> after the close yesterday.</li><li>Adding to the sour mood is a statement from its auditor (10-K, F16) that the company may have to scale back its operations, even with an additional capital raise, if its prospects do not improve.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439140\" data-linked=\"Intrexon down 31% after soft Q4 results, capital needs\" data-tweet=\"$XON - Intrexon down 31% after soft Q4 results, capital needs https://seekingalpha.com/news/3439140-intrexon-down-31-after-soft-q4-results-capital-needs?source=tweet\" data-url=\"https://seekingalpha.com/news/3439140-intrexon-down-31-after-soft-q4-results-capital-needs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439150\" data-ts=\"1551453729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPIC\" target=\"_blank\">TPIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439150-tpi-compositesminus-6-after-q4-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TPI Composites -6% after Q4 earnings miss</a></h4><ul><li>TPI Composites (<a href='https://seekingalpha.com/symbol/TPIC' title='TPI Composites'>TPIC</a> <font color=\"red\">-6%</font>) reported Q4 revenue growth of 14.4% Y/Y to $290.06M, and total billings of $304.8M (+25.6% Y/Y).</li><li>Net sales of wind blades were $257.8M (+11.6% Y/Y), driven by a 3% increase in the number of wind blades produced and higher average sales prices.</li><li>Q4 Gross margin <font color=\"red\">declined by 763 bps</font> to 4.3%; and operating margin <font color=\"red\">declined by 850 bps</font> to -1.3%.</li><li>Adj. EBITDA was $9.75M a decrease of 65.7% Y/Y and margin<font color=\"red\"> declined by 785 bps</font> to 3.4%.</li><li>Net cash used in operating activities for the quarter was $20.45M, compared to cash provided of $31.14M a year ago.</li><li>Free cash flow for the quarter was negative $22.51M.</li><li>Company has Cash, cash equivalents and restricted cash of $89.37M, as of December 31, 2018.</li><li><strong>FY19 Guidance: </strong>Net sales and total billings $1.5B to $1.6B; Adj. EBITDA $120M to $130M; EPS $1.34 to $1.45; avg. sales price per blade $135k to $140k; effective tax rate 20%-25%; and Capex $95M to $100M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438700-tpi-composites-misses-0_22-misses-revenue\" target=\"_blank\">TPI Composites misses by $0.22, misses on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439150\" data-linked=\"TPI Composites -6% after Q4 earnings miss\" data-tweet=\"$TPIC - TPI Composites -6% after Q4 earnings miss https://seekingalpha.com/news/3439150-tpi-compositesminus-6-after-q4-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3439150-tpi-compositesminus-6-after-q4-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439148\" data-ts=\"1551453562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439148-analysts-boost-vmware-targets-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts boost VMware targets after earnings</a></h4><ul><li>Jefferies reiterates a Buy rating on VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>) and raises the target from $196 to $203 praising the <a href=\"https://seekingalpha.com/news/3438827-vmware-plus-3-percent-q4-beats-licensing-growth\" target=\"_blank\">quarter's performance</a> and citing field work showing customers going all-in on VMW.</li><li>Credit Suisse stays on the sidelines but increases the PT from $160 to $185, noting that Dell synergies of $1B have been achieved about a year ahead of the three-year schedule.</li><li>Oppenheimer sticks with Outperform and shifts from $170 to $190 as VMW benefits from broadband strength.</li><li>The firm expects momentum to carry into FY20 as the portfolio broadens and the deepening relationship with Amazon Web Services delivers more results.</li><li>VMware shares are <font color=\"green\">up 4.3%</font> to $179.12.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439148\" data-linked=\"Analysts boost VMware targets after earnings\" data-tweet=\"$VMW - Analysts boost VMware targets after earnings https://seekingalpha.com/news/3439148-analysts-boost-vmware-targets-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3439148-analysts-boost-vmware-targets-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439143\" data-ts=\"1551453440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439143-intrexon-plunges-nearly-30-after-going-concern-disclosure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon plunges nearly 30% after &#39;going concern&#39; disclosure</a></h4><ul><li>Alongside Q4 results, the company said it expects to include a \"going concern\" statement in its annual report.</li><li>That's enough for Northland bull Robert Breza to throw in the towel, downgrading to Market Perform from Outperform. The disclosure, he says, will have investors taking a \"wait and see attitude\" until a way forward becomes clearer.</li><li><a href=\"https://seekingalpha.com/filing/4381680\" target=\"_blank\">10-K is here</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3438770-intrexon-beats-0_13-beats-revenue\" target=\"_blank\">Intrexon beats by $0.13, beats on revenue</a> (Feb. 28)</li><li><a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color=\"red\">-29.3%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3439143\" data-linked=\"Intrexon plunges nearly 30% after &#39;going concern&#39; disclosure\" data-tweet=\"$XON - Intrexon plunges nearly 30% after &#39;going concern&#39; disclosure https://seekingalpha.com/news/3439143-intrexon-plunges-nearly-30-after-going-concern-disclosure?source=tweet\" data-url=\"https://seekingalpha.com/news/3439143-intrexon-plunges-nearly-30-after-going-concern-disclosure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439139\" data-ts=\"1551452826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNFT\" target=\"_blank\">BNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439139-benefitfocusminus-6-on-secondary-offering-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Benefitfocus -6% on secondary offering pricing</a></h4><ul><li>Benefitfocus (NASDAQ:<a href='https://seekingalpha.com/symbol/BNFT' title='Benefitfocus, Inc.'>BNFT</a>)<font color=\"red\"> drops 5.7%</font> after <a href=\"https://seekingalpha.com/pr/17429918-benefitfocus-announces-pricing-secondary-offering\" target=\"_blank\">pricing </a>its secondary offering of about 5.7M shares at $48.25 per share.</li><li>The share sale is coming from funds managed by Goldman Sachs and Mercer, who have granted the underwriters a 30-day option to purchase 855K additional shares.</li><li>Benefitfocus won't receive any proceeds from the sale.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439139\" data-linked=\"Benefitfocus -6% on secondary offering pricing\" data-tweet=\"$BNFT - Benefitfocus -6% on secondary offering pricing https://seekingalpha.com/news/3439139-benefitfocusminus-6-on-secondary-offering-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3439139-benefitfocusminus-6-on-secondary-offering-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439133\" data-ts=\"1551452342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSP\" target=\"_blank\">SSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439133-scrippsplus-2_6-after-sharp-revenue-gain-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scripps +2.6% after sharp revenue gain in Q4</a></h4><ul>   <li>E.W. Scripps (NASDAQ:<a href='https://seekingalpha.com/symbol/SSP' title='The E.W. Scripps Company'>SSP</a>) is <font color=\"green\">up 2.6%</font> after its revenues jumped 41% in Q4 and profitability more than doubled.</li>    <li>Income from continuing operations was $36M, vs. a year-ago $11.5M.</li>    <li>Revenues by segment: Local Media, $281.4M (up 39.1%); National Media, $85.5M (up 47.5%); Other, $1.2M (down 15.5%).</li>    <li>Cash and equivalents were $107M at Dec. 31, against total debt of $696M.</li>    <li>\"Looking ahead, we are focused on continuing to seek opportunities to bolster the durability and reach of our portfolio,\" says CEO Adam Symson. \"Scripps also continues to grow its retransmission revenue and will benefit in less than a year from the reset of its Comcast contract on Dec. 31, 2019.\"</li>    <li>For Q1, it sees local media revenue up in the mid-single digits and retransmission revenue up in the high teens, as well as national media revenue in the low to mid-$80M range. It's also forecasting capital expenditures in the high-single-digit millions.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439024-e-w-scripps-misses-0_13-beats-revenue\" target=\"_blank\">E.W. Scripps misses by $0.13, beats on revenue</a> (Mar. 01 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17429908-scripps-reports-fourth-quarter-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439133\" data-linked=\"Scripps +2.6% after sharp revenue gain in Q4\" data-tweet=\"$SSP - Scripps +2.6% after sharp revenue gain in Q4 https://seekingalpha.com/news/3439133-scrippsplus-2_6-after-sharp-revenue-gain-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3439133-scrippsplus-2_6-after-sharp-revenue-gain-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439131\" data-ts=\"1551452206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439131-endo-down-3-on-positive-cch-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo down 3% on &quot;positive&quot; CCH data</a></h4><ul><li>Tomorrow, Endo International plc (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"red\">-2.5%</font>) will be presenting \"<a href=\"https://seekingalpha.com/pr/17429910-endo-will-showcase-late-breaking-phase-3-cch-data-2019-american-academy-dermatology-annual\" target=\"_blank\">new data</a>\" from two Phase 3 clinical trials, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03428750?lead=endo&amp;phase=2&amp;rank=3\" target=\"_blank\">RELEASE-1</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT03446781?lead=endo&amp;phase=2&amp;rank=2\" target=\"_blank\">RELEASE-2</a>, evaluating its collagenase clostridium histolyticum &#40;CCH&#41; in women with buttock-area cellulite at the American Academy of Dermatology Annual Meeting in Washington, DC.</li><li>The company's confusing way of explaining the results makes it difficult to determine if the studies successfully met the co-primary endpoints of improvements of at least two levels in patient-reported and clinician-reported cellulite severity scales.</li><li>It says a \"greater percentage\" of the 843 total subjects (423 in R-1 and 420 in R-2) who were treated with CCH met the primary of endpoint of response compared to placebo, providing p values, but not the actual proportions.</li><li>R-1 apparently met all (8/8) secondary endpoints while R-2 met 7/8.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439131\" data-linked=\"Endo down 3% on &quot;positive&quot; CCH data\" data-tweet=\"$ENDP - Endo down 3% on &quot;positive&quot; CCH data https://seekingalpha.com/news/3439131-endo-down-3-on-positive-cch-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439131-endo-down-3-on-positive-cch-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439128\" data-ts=\"1551451442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIRK\" target=\"_blank\">KIRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439128-kirklands-sheds-14-after-profit-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kirkland&#39;s sheds 14% after profit guidance cut</a></h4><ul> <li>Kirkland's (NASDAQ:<a href='https://seekingalpha.com/symbol/KIRK' title='Kirkland&#39;s, Inc.'>KIRK</a>) <font color=\"red\">falls 14.0%</font> after dropping its full-year profit guidance well below the expectation of analysts.</li> <li>The retailer sees FY19 EPS of ~$0.38 vs. $0.56 consensus.</li> <li>Shares of Kirkland's are still up 5.7% YTD.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439045-kirklands-reports-q4-sales-updates-2018-outlook\" target=\"_blank\">Kirkland's reports Q4 sales and updates 2018 outlook</a> (March 1)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439128\" data-linked=\"Kirkland&#39;s sheds 14% after profit guidance cut\" data-tweet=\"$KIRK - Kirkland&#39;s sheds 14% after profit guidance cut https://seekingalpha.com/news/3439128-kirklands-sheds-14-after-profit-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3439128-kirklands-sheds-14-after-profit-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439125\" data-ts=\"1551451017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439125-overstock-com-updates-on-tzero-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock.com updates on tZERO investment</a></h4><ul> <li>Overstock.com (<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a> <font color='red'>-4.1%</font>) says the previously-announced GSR Capital equity investment in Overstock and tZERO has not been completed.</li>    <li>The company says it remains in discussions with GSR Capital and Makara Capital, a key partner of GSR Capital, regarding a potential transaction.</li><li>Overstock.com plans to release more information on its retail and blockchain properties with its upcoming earnings report.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17430163-overstock-issues-statement-regarding-proposed-tzero-equity-investment\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439125\" data-linked=\"Overstock.com updates on tZERO investment\" data-tweet=\"$OSTK $OSTBP $OSTK - Overstock.com updates on tZERO investment https://seekingalpha.com/news/3439125-overstock-com-updates-on-tzero-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3439125-overstock-com-updates-on-tzero-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439118\" data-ts=\"1551450741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439118-capital-raise-for-energous\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital raise for Energous</a></h4><ul><li>Underwritten by Roth Capital Partners, Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) is <a href=\"https://seekingalpha.com/filing/4381895\" target=\"_blank\">selling 3.33M shares</a> and 1.67M warrants.</li><li>The stock's <font color=\"green\">higher by 1%</font> premarket to $5.82, but investors appear to have already discounted the raise, sending shares down nearly 50% over the past 10 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439118\" data-linked=\"Capital raise for Energous\" data-tweet=\"$WATT - Capital raise for Energous https://seekingalpha.com/news/3439118-capital-raise-for-energous?source=tweet\" data-url=\"https://seekingalpha.com/news/3439118-capital-raise-for-energous\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439114\" data-ts=\"1551450157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOMX\" target=\"_blank\">FOMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439114-foamix-pharmaceuticalsplus-2-on-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foamix Pharmaceuticals +2% on FY results</a></h4><ul><li>Foamix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a>) <a href=\"https://seekingalpha.com/pr/17429203-foamix-reports-fiscal-year-2018-financial-results-provides-corporate-update\" target=\"_blank\">FY results</a>: Revenues: $3.6M (-2.7%).</li><li>Net Loss: ($74.2M) (-12.9%); Loss Per Share: ($1.70) (+3.4%); Quick Assets: $98.6M (46.7%).</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438792-foamix-pharmaceuticals-reports-fy-results\" target=\"_blank\">Foamix Pharmaceuticals reports FY results</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439114\" data-linked=\"Foamix Pharmaceuticals +2% on FY results\" data-tweet=\"$FOMX - Foamix Pharmaceuticals +2% on FY results https://seekingalpha.com/news/3439114-foamix-pharmaceuticalsplus-2-on-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3439114-foamix-pharmaceuticalsplus-2-on-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439113\" data-ts=\"1551450076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439113-maxarminus-22-analysts-absorb-rough-quarter-dividend-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar -22% as analysts absorb rough quarter, dividend cut</a></h4><ul>   <li>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) is <font color=\"red\">22% lower</font> premarket following yesterday's earnings, where it <a href=\"https://seekingalpha.com/news/3438923-maxar-minus-15-percent-revenue-miss-dividend-cut\" target=\"_blank\">missed revenue expectations</a> and trimmed its dividend to a penny per quarter.</li>    <li>That earned the stock downgrades: CIBC Capital Markets has cut to Underperform from Neutral, and trimmed its price target to $5 from %6, implying 32% downside from yesterday.</li>    <li>For its part, TD Securities has cut to Hold from Speculative Buy.</li>    <li><a href=\"https://seekingalpha.com/article/4245588-maxar-technologies-inc-maxr-ceo-dan-jablonsky-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439113\" data-linked=\"Maxar -22% as analysts absorb rough quarter, dividend cut\" data-tweet=\"$MAXR - Maxar -22% as analysts absorb rough quarter, dividend cut https://seekingalpha.com/news/3439113-maxarminus-22-analysts-absorb-rough-quarter-dividend-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3439113-maxarminus-22-analysts-absorb-rough-quarter-dividend-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439112\" data-ts=\"1551449948\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORE\" target=\"_blank\">CORE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439112-core-mark-holding-beat-estimates-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Core-Mark Holding beat estimates in Q4</a></h4><ul><li>Core-Mark Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/CORE' title='Core-Mark Holding Company, Inc.'>CORE</a>) reports Non-cigarette sales rose 5.7% in <a href=\"https://seekingalpha.com/pr/17429945-core-mark-announces-2018-fourth-quarter-full-year-financial-results\" target=\"_blank\">Q4</a>, primarily due to the growing popularity of alternative nicotine delivery products, and strong sales of candy and fresh foods.</li><li>Cigarette sales dropped 2%, driven by declines in cigarette consumption.</li><li>Gross margin rate improved 17 bps to 5.31%, driven by a shift in sales mix towards higher margin non-cigarette products.</li><li>Adjusted EBITDA up 2.4% to $39M.</li><li><strong>FY2019 Guidance</strong>: Net sales: $16.8 to $17B; Adjusted EBITDA: $176 to $182M; Diluted EPS: 1.09 to $1.19; Diluted EPS (excl. LIFO expense): $1.50 to $1.60; Capex: ~$30M; Tax rate: 25%; Fully diluted shares outstanding: 46M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439057-core-mark-holding-beats-0_03-beats-revenue\" target=\"_blank\">Core-Mark Holding beats by $0.03, beats on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439112\" data-linked=\"Core-Mark Holding beat estimates in Q4\" data-tweet=\"$CORE - Core-Mark Holding beat estimates in Q4 https://seekingalpha.com/news/3439112-core-mark-holding-beat-estimates-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3439112-core-mark-holding-beat-estimates-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439110\" data-ts=\"1551449793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439110-earnings-movers-lead-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Earnings movers lead premarket gainers</a></h4><ul><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) <font color=\"green\">+30%</font> on <a href=\"https://seekingalpha.com/news/3438744-puma-biotechnology-beats-0_37-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>) <font color=\"green\">+22%</font> on <a href=\"https://seekingalpha.com/news/3438738-funko-beats-0_10-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>The Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/news/3438755-gap-beats-0_05-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Farfetch (NYSE:<a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch'>FTCH</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3438859-farfetch-beats-0_06-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3438731-zscaler-beats-0_10-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>DENTSPLY SIRONA (NASDAQ:<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA, Inc'>XRAY</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3438982-dentsply-sirona-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Foot Locker (NYSE:<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3438986-foot-locker-beats-0_16-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>AMC Entertainment Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3438763-amc-entertainment-beats-0_22-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix Inc'>EBIX</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3439049-ebix-beats-0_11-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Omeros (NASDAQ:<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3439025-omeros-beats-0_26-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) <font color=\"green\">+6%</font> as European advisory group <a href=\"https://seekingalpha.com/news/3439080-european-advisory-group-backs-sanofis-zynquista-t1d\" target=\"_blank\">backs Sanofi's Zynquista</a> in T1D.</li><li>Capri Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CPRI' title='Capri Holdings Limited'>CPRI</a>) <font color=\"green\">+6%</font> on positive <a href=\"https://seekingalpha.com/news/3439016-jefferies-sees-capri-holdings-undervalued\" target=\"_blank\">analyst action</a>.</li><li>Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3438703-splunk-beats-0_17-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439110\" data-linked=\"Earnings movers lead premarket gainers\" data-tweet=\"$PBYI $FNKO $GPS - Earnings movers lead premarket gainers https://seekingalpha.com/news/3439110-earnings-movers-lead-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439110-earnings-movers-lead-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439107\" data-ts=\"1551449693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439107-european-advisory-group-backs-expanded-labeling-for-gileads-viread\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs expanded labeling for Gilead&#39;s Viread</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viread-ii-191_en.pdf\" target=\"_blank\">positive opinion</a> recommending revising labeling for Gilead Sciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) Viread (tenofovir disoproxil).</li><li>Viread 123 mg, 163 mg and 204 mg: for the treatment of chronic hepatitis B virus &#40;HBV&#41; infection in pediatric patients ages 6 to less than 12 years old who weigh 28 kg to less than 35 kg with compensated liver disease and evidence of immune-active disease (i.e., active viral replication and persistently high ALT levels or histological evidence of moderate-to-severe inflammation and/or fibrosis).</li><li>Viread 33 mg/g granules: for the treatment of chronic HBV infection in pediatric patients at least two years old for whom a solid dosage form is inappropriate.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439107\" data-linked=\"European advisory group backs expanded labeling for Gilead&#39;s Viread\" data-tweet=\"$GILD - European advisory group backs expanded labeling for Gilead&#39;s Viread https://seekingalpha.com/news/3439107-european-advisory-group-backs-expanded-labeling-for-gileads-viread?source=tweet\" data-url=\"https://seekingalpha.com/news/3439107-european-advisory-group-backs-expanded-labeling-for-gileads-viread\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439102\" data-ts=\"1551449606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTZ\" target=\"_blank\">MTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439102-mastecplus-2_5-on-q4-earnings-beats-provides-1q19-and-fy19-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MasTec +2.5% on Q4 earnings beats; provides 1Q19 and FY19 guidance</a></h4><ul><li>MasTec (NYSE:<a href='https://seekingalpha.com/symbol/MTZ' title='MasTec, Inc.'>MTZ</a>) reported Q4 revenue growth of 20% Y/Y to $1.92B. Segment revenues: Communications $649.3M (-1.9% Y/Y); Oil and Gas $947.1M (+28% Y/Y); Electrical Transmission $99.7M (-1.3% Y/Y); and Power Generation and Industrial $221.7M (+131.7% Y/Y).</li><li>Q4 Adj. EBITDA increased by 51.9% Y/Y to $195.8M and margin <font color=\"green\">expanded by 217 bps</font> to 10.2%.</li><li>Segment Adj. EBITDA margins: Communications 9.2% <font color=\"red\">down by 200 bps</font>; Oil and Gas 14.8% <font color=\"green\">up by 860 bps</font>; Electrical Transmission 5.6% <font color=\"red\">down by 70 bps</font>; and Power Generation and Industrial 7.3% <font color=\"red\">down by 80 bps</font>.</li><li>Company repurchased 2.9M shares in the quarter and total of 7.2M shares for FY18.</li><li>Net cash provided by operating activities YTD was $529.95M, compared to $144.09 a year ago; and Free cash flow of $389M.</li><li><strong>1Q19 Guidance: </strong>Revenue ~$1.4B; GAAP EPS $0.39; Non-GAAP EPS $0.43; and Adj. EBITDA ~$126M or 9% of revenue.</li><li><strong>FY19 Guidance: </strong>Revenue ~$7.6B; GAAP EPS $4.20; Adj. EPS $4.34; and Adj. EBITDA ~$780M or 10.3% of revenue.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438824-mastec-beats-0_01-beats-revenue\" target=\"_blank\">MasTec beats by $0.01, beats on revenue</a> (Feb. 28)</li><li>Shares <font color=\"green\">+2.59%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3439102\" data-linked=\"MasTec +2.5% on Q4 earnings beats; provides 1Q19 and FY19 guidance\" data-tweet=\"$MTZ - MasTec +2.5% on Q4 earnings beats; provides 1Q19 and FY19 guidance https://seekingalpha.com/news/3439102-mastecplus-2_5-on-q4-earnings-beats-provides-1q19-and-fy19-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3439102-mastecplus-2_5-on-q4-earnings-beats-provides-1q19-and-fy19-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439105\" data-ts=\"1551449596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439105-ntnx-and-wuba-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NTNX and WUBA among premarket losers</a></h4><ul><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"red\">-46%</font> after mirvetuximab soravtansine <a href=\"https://seekingalpha.com/news/3438987-immunogens-mirvetuximab-soravtansine-flunks-late-stage-study-shares-43-percent-premarket\" target=\"_blank\">flunks</a> late-stage study.</li><li>Mersana Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRSN' title='Mersana Therapeutics'>MRSN</a>) <font color=\"red\">-28%</font> on <a href=\"https://seekingalpha.com/news/3439011-mersana-therapeutics-29-percent-premarket-stock-offering\" target=\"_blank\">stock offering</a>.</li><li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) <font color=\"red\">-25%</font> on <a href=\"https://seekingalpha.com/news/3438711-nutanix-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) <font color=\"red\">-25%</font> on <a href=\"https://seekingalpha.com/news/3438808-maxar-technologies-eps-16_10\" target=\"_blank\">Q4 earnings</a>.</li><li>Intrexon (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <font color=\"red\">-16%</font> on <a href=\"https://seekingalpha.com/news/3438770-intrexon-beats-0_13-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) <font color=\"red\">-13%</font>.</li><li>PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIIK' title='PHI, Inc. - Non'>PHIIK</a>) <font color=\"red\">-10%</font>.</li><li>58.com (NYSE:<a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3438919-58-com-beats-0_18-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) <font color=\"red\">-6%</font>.</li><li>Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3438726-pure-storage-misses-0_04-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <font color=\"red\">-6%</font> on planned <a href=\"https://seekingalpha.com/news/3438830-tg-therapeutics-6-percent-hours-planned-capital-raise\" target=\"_blank\">capital raise</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439105\" data-linked=\"NTNX and WUBA among premarket losers\" data-tweet=\"$IMGN $MRSN $NTNX - NTNX and WUBA among premarket losers https://seekingalpha.com/news/3439105-ntnx-and-wuba-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439105-ntnx-and-wuba-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439104\" data-ts=\"1551449572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBIX\" target=\"_blank\">EBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439104-ebixplus-6-on-q4-beats-auditor-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ebix +6% on Q4 beats, auditor update</a></h4><ul><li>Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix Inc'>EBIX</a>) shares are <font color=\"green\">up 6%</font> after posting Q4 beats with 34% Y/Y revenue growth. The company says auditors have concluded Ebix successfully remediated internal control weaknesses in the areas of income taxes and business combinations.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439049-ebix-beats-0_11-beats-revenue\" target=\"_blank\">Ebix beats by $0.11, beats on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439104\" data-linked=\"Ebix +6% on Q4 beats, auditor update\" data-tweet=\"$EBIX - Ebix +6% on Q4 beats, auditor update https://seekingalpha.com/news/3439104-ebixplus-6-on-q4-beats-auditor-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3439104-ebixplus-6-on-q4-beats-auditor-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439099\" data-ts=\"1551448902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439099-european-advisory-group-backs-astrazenecas-lynparza-in-breast-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs AstraZeneca&#39;s Lynparza in breast cancer</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-20_en.pdf\" target=\"_blank\">positive opinion</a> recommending approval for AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) PARP inhibitor Lynparza (olaparib) for adult patients with BRCA1/2 mutations who have HER2-negative locally advanced or metastatic breast cancer. Unless contraindicated, patients should have been previously treated with an anthracycline and a taxane (both chemo agents) in the (neo)adjuvant or metastatic setting.</li><li>Lynparza is currently approved in Europe for ovarian, fallopian tube or primary peritoneal cancer.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Shares are down <font color=\"red\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439099\" data-linked=\"European advisory group backs AstraZeneca&#39;s Lynparza in breast cancer\" data-tweet=\"$AZN - European advisory group backs AstraZeneca&#39;s Lynparza in breast cancer https://seekingalpha.com/news/3439099-european-advisory-group-backs-astrazenecas-lynparza-in-breast-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3439099-european-advisory-group-backs-astrazenecas-lynparza-in-breast-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439093\" data-ts=\"1551448297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRM\" target=\"_blank\">ALRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439093-alarm-comminus-6-off-record-high-q4-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alarm.com -6% off record high, Q4 beats</a></h4><ul><li>Alarm.com (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRM' title='Alarm.com'>ALRM</a>) <font color=\"red\">drops 6.3% </font>pre-market after a record close yesterday. The company reported Q4 beats with an in-line FY forecast. SaaS and license revenue increased 19% in the quarter to $77.8M.</li><li>FY19 outlook has revenue from $440M to $450M (consensus: $438.93M) and EPS from $1.37 to $1.41 (consensus: $1.38).</li><li>Analyst reaction: Raymond James reiterates a Strong Buy and raises the PT from $58 to $70 saying the firm's optimism about the expanded ADT relationship seems to be materializing.</li><li>Goldman Sachs reiterates its Sell rating and increases the target by a dollar to $43, staying the Street-low PT.</li><li>The firm praises Alarm's execution and ongoing smart home security transition, but takes \"a more guarded stance on medium-term fundamentals given ongoing changes in the connected home ecosystem.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438743-alarm-com-beats-0_05-beats-revenue\" target=\"_blank\">Alarm.com beats by $0.05, beats on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439093\" data-linked=\"Alarm.com -6% off record high, Q4 beats\" data-tweet=\"$ALRM - Alarm.com -6% off record high, Q4 beats https://seekingalpha.com/news/3439093-alarm-comminus-6-off-record-high-q4-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3439093-alarm-comminus-6-off-record-high-q4-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439091\" data-ts=\"1551448094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439091-european-advisory-group-backs-sanofis-dupixent-for-asthma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Sanofi&#39;s Dupixent for asthma</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/en/news/new-add-treatment-patients-severe-asthma\" target=\"_blank\">positive opinion</a> recommending approval for Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) Dupixent (dupilumab) as add-on maintenance treatment for patients at least 12 years old with certain types of severe asthma.</li><li>Dupixent is currently approved in Europe for atopic dermatitis.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>SNY is up <font color=\"green\">1%</font> premarket on light volume.</li><li>Related ticker: Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439091\" data-linked=\"European advisory group backs Sanofi&#39;s Dupixent for asthma\" data-tweet=\"$SNY $REGN - European advisory group backs Sanofi&#39;s Dupixent for asthma https://seekingalpha.com/news/3439091-european-advisory-group-backs-sanofis-dupixent-for-asthma?source=tweet\" data-url=\"https://seekingalpha.com/news/3439091-european-advisory-group-backs-sanofis-dupixent-for-asthma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439081\" data-ts=\"1551447320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNK\" target=\"_blank\">FNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439081-funkoplus-17-after-sales-growth-dazzles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Funko +17% after sales growth dazzles</a></h4><ul> <li>Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>) <font color=\"green\">rallies 17.45%</font> in premarket trading after posting strong sales in <a href=\"https://seekingalpha.com/pr/17429280-funko-reports-fourth-quarter-fiscal-2018-financial-results\" target=\"_blank\">Q4</a>. U.S. sales were up 30% during the quarter and international sales were 58% higher.</li> <li>The pop culture collectibles company's guidance is also impressing investors. Funko expects full-year revenue of $810M to $825M vs. $740M consensus and EPS of $1.05 to $1.15 vs. $0.97 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438738-funko-beats-0_10-beats-revenue\" target=\"_blank\">Funko beats by $0.10, beats on revenue</a> (Feb. 28)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439081\" data-linked=\"Funko +17% after sales growth dazzles\" data-tweet=\"$FNK $FNKO - Funko +17% after sales growth dazzles https://seekingalpha.com/news/3439081-funkoplus-17-after-sales-growth-dazzles?source=tweet\" data-url=\"https://seekingalpha.com/news/3439081-funkoplus-17-after-sales-growth-dazzles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439080\" data-ts=\"1551447182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439080-european-advisory-group-backs-sanofis-zynquista-in-t1d\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Sanofi&#39;s Zynquista in T1D</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynquista_en.pdf\" target=\"_blank\">positive opinion</a> recommending Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in overweight type 1 diabetics (Body Mass Index \u2265 27 kg/m2) who have failed to achieve adequate glycemic control despite optimal insulin therapy.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Related ticker: Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) (<font color=\"green\">+9% </font>premarket).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439080\" data-linked=\"European advisory group backs Sanofi&#39;s Zynquista in T1D\" data-tweet=\"$SNY $LXRX - European advisory group backs Sanofi&#39;s Zynquista in T1D https://seekingalpha.com/news/3439080-european-advisory-group-backs-sanofis-zynquista-in-t1d?source=tweet\" data-url=\"https://seekingalpha.com/news/3439080-european-advisory-group-backs-sanofis-zynquista-in-t1d\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439077\" data-ts=\"1551447026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADSK\" target=\"_blank\">ADSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439077-autodeskplus-3-on-q4-beats-billings-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autodesk +3% on Q4 beats with billings strength</a></h4><ul><li>Autodesk (NASDAQ:<a href='https://seekingalpha.com/symbol/ADSK' title='Autodesk, Inc.'>ADSK</a>)<font color=\"green\"> </font><font color=\"green\">gains 2.8%</font> after yesterday's Q4 beats with revenue up 33% Y/Y. Billings beat estimates with $1.04B versus the $952.2M consensus and ADSK added 418K subscription customers while shedding 166K from maintenance.</li><li>Mixed Q1 guidance has upside revenue from $735M to $745M (consensus: $721.14M) and downside EPS from $0.44 to $0.48 (consensus: $0.57).</li><li>The FY20 outlook puts revenue from $3.25B to $3.3B (consensus: $3.27B) and EPS from $2.71 to $2.90 (consensus: $3.14).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438698-autodesk-beats-0_04-beats-revenue\" target=\"_blank\">Autodesk beats by $0.04, beats on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439077\" data-linked=\"Autodesk +3% on Q4 beats with billings strength\" data-tweet=\"$ADSK - Autodesk +3% on Q4 beats with billings strength https://seekingalpha.com/news/3439077-autodeskplus-3-on-q4-beats-billings-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3439077-autodeskplus-3-on-q4-beats-billings-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439075\" data-ts=\"1551446874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439075-ebayplus-3-after-announcing-strategic-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EBay +3% after announcing strategic review</a></h4><ul> <li>EBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) announces a series of new initiatives aimed at improving performance. The new measures include an operating review and the commencement of a strategic review of a portfolio of assets such as StubHub and eBay Classifieds Group.</li><li>The company says it's working with Elliott Management, Starboard Value and other shareholders on the initiatives. Cooperation agreements with Elliott and Starboard have been inked.</li>                 <li>EBAY  <font color=\"green\">+3.30%</font> premarket to  $38.40.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/17429932-ebay-announces-strategic-initiatives-enhance-performance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439075\" data-linked=\"EBay +3% after announcing strategic review\" data-tweet=\"$EBAY - EBay +3% after announcing strategic review https://seekingalpha.com/news/3439075-ebayplus-3-after-announcing-strategic-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3439075-ebayplus-3-after-announcing-strategic-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439074\" data-ts=\"1551446760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439074-european-advisory-group-backs-pfizers-lorlatinib-for-certain-type-of-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Pfizer&#39;s lorlatinib for certain type of lung cancer</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lorviqua_en.pdf\" target=\"_blank\">positive opinio</a>n recommending conditional approval for Pfizer's (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) Lorviqua (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase &#40;ALK&#41;-positive advanced non-small cell lung cancer &#40;NSCLC&#41;.</li><li>Conditional approval means that the benefit of immediate availability of the product outweighs the risk despite the need for additional clinical data (accelerated approval).</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439074\" data-linked=\"European advisory group backs Pfizer&#39;s lorlatinib for certain type of lung cancer\" data-tweet=\"$PFE - European advisory group backs Pfizer&#39;s lorlatinib for certain type of lung cancer https://seekingalpha.com/news/3439074-european-advisory-group-backs-pfizers-lorlatinib-for-certain-type-of-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3439074-european-advisory-group-backs-pfizers-lorlatinib-for-certain-type-of-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439072\" data-ts=\"1551446559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAR\" target=\"_blank\">MAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439072-marriott-internationalminus-1-after-profit-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marriott International -1% after profit guidance disappoints</a></h4><ul> <li>Marriott International (NYSE:<a href='https://seekingalpha.com/symbol/MAR' title='Marriott International, Inc.'>MAR</a>) dips after <a href=\"https://seekingalpha.com/pr/17429434-marriott-international-reports-fourth-quarter-2018-results\" target=\"_blank\">guiding</a> its full-year profit outlook below expectations.</li> <li>The hotel operator sees full-year EPS of $5.87 to $6.19 vs. $6.30 consensus. The forecast is based off an expectation for comparable systemwide RevPAR growth of +1 to +3% in North America and +2 to +4% outside North America.</li> <li>Shares of Marriott are <font color=\"red\">down 1.21%</font> in premarket trading to $123.75.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438809-marriott-beats-0_05-beats-revenue\" target=\"_blank\">Marriott beats by $0.05, beats on revenue</a> (Feb. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439072\" data-linked=\"Marriott International -1% after profit guidance disappoints\" data-tweet=\"$MAR - Marriott International -1% after profit guidance disappoints https://seekingalpha.com/news/3439072-marriott-internationalminus-1-after-profit-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3439072-marriott-internationalminus-1-after-profit-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439065\" data-ts=\"1551446343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCO\" target=\"_blank\">DCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439065-ducommunsplus-3-on-q4-earnings-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ducommun&#39;s +3% on Q4 earnings beats</a></h4><div><ul><li>Ducommun (NYSE:<a href='https://seekingalpha.com/symbol/DCO' title='Ducommun Inc'>DCO</a>) reported Q4 growth of 15.4% Y/Y to $164.2M, reflecting $17M higher revenue in commercial aerospace end-use markets; $8.1M higher revenue in military and space end-use markets and $3.2M lowers revenue in industrial end-use markets.</li><li>Electronic Systems revenue $85.26M (+10.5% Y/Y) and Adj. EBITDA margin of 15.4%<font color=\"red\"> down by 170 bps</font>.</li><li>Structural Systems revenue $78.92M (+21.3% Y/Y) and Adj. EBITDA margin of 12.7% <font color=\"green\">up by 470 bps</font>.</li><li>Q4 Gross margin <font color=\"green\">improved by 180 bps</font> to 19.9%; and operating margin <font color=\"green\">recovered by 564 bps</font> to 3.8%.</li><li>Adj. EBITDA was $19.38M and margin of 11.8% <font color=\"green\">up by 210 bps</font>.</li><li>SG&amp;A expenses were $22.53M (+12.3% Y/Y) and margin <font color=\"green\">declined by 38 bps</font> to 13.7%.</li><li>Backlog was $864.4M as of December 31, 2018, compared to $726.5M a year ago.</li><li>Company has cash and cash equivalents of $10.26M as of December 31, 2108.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438771-ducommun-beats-0_11-beats-revenue\" target=\"_blank\">Ducommun beats by $0.11, beats on revenue</a> (Feb. 28)</li><li>Shares <font color=\"green\">+3.6% </font>premarket</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3439065\" data-linked=\"Ducommun&#39;s +3% on Q4 earnings beats\" data-tweet=\"$DCO - Ducommun&#39;s +3% on Q4 earnings beats https://seekingalpha.com/news/3439065-ducommunsplus-3-on-q4-earnings-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3439065-ducommunsplus-3-on-q4-earnings-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439069\" data-ts=\"1551446324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTG\" target=\"_blank\">PSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439069-pure-storageminus-5-ofter-q4-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pure Storage -5% ofter Q4 misses</a></h4><ul><li>Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a>) drops 4.8% after Q4 results that missed EPS and revenue estimates and included in-line guidance.</li><li>Q1 expects revenue of $327M to $339M (consensus: $332.47M), non-GAAP gross margin from 65% to 68%, and non-GAAP operating margin from -8.5% to -4.5%.</li><li>FY20 outlook has revenue from $1.735B to $1.805B (consensus: $1.76B), non-GAAP gross margin from 65% to 68%, and operating margin from 3% to 7%.</li><li>In Q4, Product revenue missed estimates with $340.1M versus the $362.9M consensus. Support revenue came in at $82.1M, above the $80.3M consensus.</li><li>Q4 gross margin was 67.6%, a percentage point above consensus, and operating margin was 7.4%, below the expected 10.5%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438726-pure-storage-misses-0_04-misses-revenue\" target=\"_blank\">Pure Storage misses by $0.04, misses on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439069\" data-linked=\"Pure Storage -5% ofter Q4 misses\" data-tweet=\"$PSTG - Pure Storage -5% ofter Q4 misses https://seekingalpha.com/news/3439069-pure-storageminus-5-ofter-q4-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3439069-pure-storageminus-5-ofter-q4-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439064\" data-ts=\"1551446205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439064-portola-pharma-q4-op-line-up-56-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma Q4 op line up 56%; shares up 6% premarket</a></h4><ul><li>Portola Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <a href=\"https://seekingalpha.com/pr/17430017-portola-pharmaceuticals-reports-fourth-quarter-full-year-2018-financial-results-provides\" target=\"_blank\">Q4 results</a>: Revenues: $15.3M (+56.1%); Product revenue: $14.1M; Collaboration and license revenue: $1.2M.</li><li>Net Loss: ($88.5M) (+3.6%); Non-GAAP Net Loss: ($69M); Loss Per Share: ($1.34) (+5.0%); Non-GAAP Loss Per Share: ($1.04); Quick Assets: $317M (-40.7%).</li><li>Shares are up <font color=\"green\">6%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-revenue\" target=\"_blank\">Portola Pharmaceuticals beats by $0.07, beats on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439064\" data-linked=\"Portola Pharma Q4 op line up 56%; shares up 6% premarket\" data-tweet=\"$PTLA - Portola Pharma Q4 op line up 56%; shares up 6% premarket https://seekingalpha.com/news/3439064-portola-pharma-q4-op-line-up-56-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3439064-portola-pharma-q4-op-line-up-56-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439056\" data-ts=\"1551445618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439056-portola-pharmaceuticals-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharmaceuticals beats by $0.07, beats on revenue</a></h4><ul><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>): Q4 Non-GAAP EPS of -$1.04 <span style=\"color:green\">beats by $0.07</span>; GAAP EPS of -$1.34 <span style=\"color:red\">misses by $0.23</span>.</li><li>Revenue of $15.3M (+56.1% Y/Y) <font color=\"green\">beats by $4.35M</font>.</li><li>Shares <font color=\"green\">+4.36%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17430017-portola-pharmaceuticals-reports-fourth-quarter-full-year-2018-financial-results-provides\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439056\" data-linked=\"Portola Pharmaceuticals beats by $0.07, beats on revenue\" data-tweet=\"$PTLA - Portola Pharmaceuticals beats by $0.07, beats on revenue https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439055\" data-ts=\"1551445597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439055-nutanixminus-24-on-downside-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix -24% on downside forecast</a></h4><ul><li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) <font color=\"red\">plunges 24%</font> after yesterday's Q2 beats were offset by downside Q3 guidance with revenue from $290M to $300M (consensus: $347.56M) and EPS at -$0.60 (consensus: -$0.28).</li><li>Q3 billings are expected from $360M to $370M and gross margin from 75% to 76%.</li><li>Analyst action: Oppenheimer downgrades Nutanix from Outperform to Perform saying that attempts to do too much and a lack of sales/marketing investments have caught up with the company.</li><li>Oppenheimer expects NTNX to lower its long-term targets at the upcoming analyst day event.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438711-nutanix-beats-0_02-beats-revenue\" target=\"_blank\">Nutanix beats by $0.02, beats on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439055\" data-linked=\"Nutanix -24% on downside forecast\" data-tweet=\"$NTNX - Nutanix -24% on downside forecast https://seekingalpha.com/news/3439055-nutanixminus-24-on-downside-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3439055-nutanixminus-24-on-downside-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439047\" data-ts=\"1551445027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVFM\" target=\"_blank\">EVFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439047-evofem-biosciencesplus-2-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evofem Biosciences +2% on Q4 results</a></h4><ul><li>Evofem Biosciences (<a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a>) <a href=\"https://seekingalpha.com/pr/17429780-evofem-biosciences-reports-fourth-quarter-year-end-2018-financial-results-provides-corporate\" target=\"_blank\">Q4 results</a>: Revenues: $0; R&amp;D Expense: $9.8M (-12.5%); SG&amp;A: $5.2M (+26.8%); Net Loss: ($15M) (+27.5%); Loss Per Share: ($0.58) (+94.5%).</li><li><strong>Upcoming Clinical Milestones</strong>: AMPREVENCE, the Phase 2b trial evaluating Amphora for the prevention of chlamydia and gonorrhea, remains on track to complete enrollment in H1 with top-line results to be reported by the end of this year.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438971-evofem-biosciences-misses-0_03\" target=\"_blank\">Evofem Biosciences misses by $0.03</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439047\" data-linked=\"Evofem Biosciences +2% on Q4 results\" data-tweet=\"$EVFM - Evofem Biosciences +2% on Q4 results https://seekingalpha.com/news/3439047-evofem-biosciencesplus-2-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3439047-evofem-biosciencesplus-2-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439046\" data-ts=\"1551444880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439046-european-advisory-group-backs-portolas-ondexxya-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group back&#39;s Portola&#39;s Ondexxya; shares up 7% premarket</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://seekingalpha.com/pr/17429923-european-chmp-adopts-positive-opinion-ondexxya-andexanet-alfa-portola-pharmaceuticals-factor\" target=\"_blank\">positive opinion</a> recommending approval for Portola Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) Factor Xa reversal agent Ondexxya (andexanet alfa).</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Shares are up <font color=\"green\">7%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439046\" data-linked=\"European advisory group back&#39;s Portola&#39;s Ondexxya; shares up 7% premarket\" data-tweet=\"$PTLA - European advisory group back&#39;s Portola&#39;s Ondexxya; shares up 7% premarket https://seekingalpha.com/news/3439046-european-advisory-group-backs-portolas-ondexxya-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3439046-european-advisory-group-backs-portolas-ondexxya-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439044\" data-ts=\"1551444820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZS\" target=\"_blank\">ZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439044-zscaler-gains-18-on-billings-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zscaler gains 18% on billings strength</a></h4><ul><li>Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) <font color=\"green\">pops 17.5%</font> after yesterday's <a href=\"https://seekingalpha.com/news/3438731-zscaler-beats-0_10-beats-revenue\" target=\"_blank\">Q2 beats </a>with upside outlooks. Billings were strong at $115M (up 74% Y/Y) versus the $90.4M consensus.</li><li>Q3 guidance has revenue from $74M to $75M (consensus: $67.97M) and EPS of $0.01 (consensus: -$0.02).</li><li>Upside FY19 sees revenue from $289M to $291M (consensus: $271.94M) and EPS from $0.11 to $0.13 (consensus: -$0.02).</li><li>Analyst reactions: Morgan Stanley maintains an Underweight rating and boosts the target from $40 to $43 citing billings growth for the target and the high multiple for the lack of an upgrade.</li><li>Goldman Sachs maintains a Neutral rating and moves the PT from $35 to $40 saying the company is \"benefitting from having the right technology at the right time.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438730-zscaler-beats-0_10-beats-revenue\" target=\"_blank\">Zscaler beats by $0.10, beats on revenue</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439044\" data-linked=\"Zscaler gains 18% on billings strength\" data-tweet=\"$ZS - Zscaler gains 18% on billings strength https://seekingalpha.com/news/3439044-zscaler-gains-18-on-billings-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3439044-zscaler-gains-18-on-billings-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439042\" data-ts=\"1551444636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439042-omerosplus-4-on-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros +4% on Q4 beat</a></h4><ul><li>Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a>) <a href=\"https://seekingalpha.com/pr/17429901-omeros-corporation-reports-fourth-quarter-year-end-2018-financial-results\" target=\"_blank\">Q4 results</a>: Revenues: $22M (+59.4%).</li><li>Net Loss: ($23.5M) (-41.6%); Loss Per Share: ($0.48) (-41.2%); Quick Assets: $60.5M (-27.7%).</li><li>The consensus Revenue and GAAP EPS estimate was $15.85M and ($0.74), respectively.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439025-omeros-beats-0_26-beats-revenue\" target=\"_blank\">Omeros beats by $0.26, beats on revenue</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439042\" data-linked=\"Omeros +4% on Q4 beat\" data-tweet=\"$OMER - Omeros +4% on Q4 beat https://seekingalpha.com/news/3439042-omerosplus-4-on-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3439042-omerosplus-4-on-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439041\" data-ts=\"1551444543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439041-puma-bio-up-29-premarket-after-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Bio up 29% premarket after Q4 beat</a></h4><ul><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) is up <font color=\"green\">29%</font> premarket on light volume after posting better-than-expected <a href=\"https://seekingalpha.com/news/3438756-puma-bio-q4-nerlynx-sales-204-percent-shares-5-percent-hours\" target=\"_blank\">Q4 results</a> after the close yesterday. Nerlynx sales were up 204%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439041\" data-linked=\"Puma Bio up 29% premarket after Q4 beat\" data-tweet=\"$PBYI - Puma Bio up 29% premarket after Q4 beat https://seekingalpha.com/news/3439041-puma-bio-up-29-premarket-after-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3439041-puma-bio-up-29-premarket-after-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}